{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/chaeeun/anaconda3/envs/py39/lib/python3.9/site-packages/tqdm/auto.py:22: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "True\n",
      "True\n",
      "cuda\n"
     ]
    }
   ],
   "source": [
    "import os \n",
    "os.environ[\"CUDA_DEVICE_ORDER\"]=\"PCI_BUS_ID\"\n",
    "os.environ[\"CUDA_VISIBLE_DEVICES\"]=\"1, 2\"\n",
    "\n",
    "import torch\n",
    "print(torch.backends.cuda.is_built())\n",
    "print(torch.cuda.is_available())\n",
    "device = torch.device('cuda' if torch.cuda.is_available() else 'cpu')\n",
    "print(device)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "## Models to run\n",
    "# bioGPT\n",
    "# bioGPT large\n",
    "# Flan-T5\n",
    "# google/pegasus-pubmed"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "from transformers import AutoConfig, AutoModelForSeq2SeqLM, AutoTokenizer\n",
    "import json\n",
    "\n",
    "# model_name = 'google/flan-t5-small'\n",
    "# model_name = 'google/flan-t5-base'\n",
    "# model_name = 'google/flan-t5-small'\n",
    "# model_name = 'google/flan-t5-xl'\n",
    "model_name = 'google/flan-t5-large'\n",
    "# model_name = 'google/flan-t5-xxl'\n",
    "# model_name = \"google/pegasus-pubmed\"\n",
    "\n",
    "config = AutoConfig.from_pretrained(model_name)\n",
    "config.n_positions = 2048\n",
    "tokenizer = AutoTokenizer.from_pretrained(model_name)\n",
    "\n",
    "if model_name == \"microsoft/BioGPT-Large\":\n",
    "    model = AutoModelForCausalLM.from_pretrained(\"microsoft/BioGPT-Large\")\n",
    "else:\n",
    "    model = AutoModelForSeq2SeqLM.from_pretrained(model_name, config=config)\n",
    "    \n",
    "model.to(device)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "## 교수님께서 주신 예시\n",
    "\n",
    "item1 = \"\"\"Here we report the characterization of the human Notch3 gene which we mapped to the CADASIL critical region. We have identified mutations in CADASIL patients that cause serious disruption of this gene, indicating that Notch3 could be the defective protein in CADASIL patients.All these missense mutations may result in severe disruption of the Notch3 protein, as suggested by the highly conserved nature of the aminoacid residues involved, particularly the cysteines that are key features of EGF likedomains24. These results indicate that these nucleotide substitutions are pathogenic mutations rather than rare polymorphisms.[1]\"\"\"\n",
    "item2 = \"\"\"Linkage studies in other families enabled further refinement of this genetic interval16,17 and identification of the mutated gene as NOTCH3 (Notch homolog 3).18[2]\"\"\"\n",
    "item3 = \"\"\"CADASIL, a hereditary vascular dementia, suggesting a role for Notch3 in vessel homeostasis (Joutel et al. 1996). CADASIL is a late-onset disorder, and neurological symptoms arise from a slowly developing systemic vasculopathy, characterized ultimately by degeneration of VSMC. ...maturation of VSMC, and ends around P28 when the artery acquires its final shape. We identify Notch3 to be the first key player of this process, by regulating cell-autonomously the arterial differentiation and maturation of VSMC.[3]\"\"\"\n",
    "\n",
    "item4 = \"There is currently no consensus on whether CADASIL mutations generate hyperactive or hypoactive Notch3 proteins with regard to downstream signaling or whether CADASIL mutations are neutral in terms of Notch signaling. Whereas the R169C mutation appeared to lead to hyperactive Notch signaling (see above), the R1031C or C455R mutations were instead shown to be hypoactive,36[1]\"\n",
    "item5 = \"We believe that increased TGFb3 reflects an inflammatory condition and even an involvement of TGFb in fibrosis in CADASIL. Support for our hypothesis is the outcome of several studies that showed NOTCH3 and TGFb1 signalling play a key role in the pathogenesis and progression of chronic cardiovascular disease.[2]\"\n",
    "item6 = \"Over time, VSMCs apoptosis leads to fibrosis and thickening of the arterial wall, progressive lumen stenosis and vascular insufficiency that makes the already poorly perfused terminal regions particularly susceptible to infarcts. SMCs degeneration is followed by the emergence of large,...[3]\"\n",
    "item7 = \"Previously published studies have shown that TGF-b signaling is closely associated with the activity of SYK, and the kinase activity of SYK is essential for the activation of some signaling receptor downstream effector molecules[25]. ...bidirectional[33]. In the present study, the activation of SYK was shown to increase the progression of peritoneal fibrosis through activation of the TGF-b1/Smad3 signaling pathway, and inhibition of TGF-b1 also resulted in down-regulation of SYK.[4]\"\n",
    "item8 = \"Our work confirms and highlights the relevance of NOTCH3 expression and signaling in pro-inflammatory macrophage activation and identified its prominent and specific role in the activation of NF-kB. A positive regulation between NOTCH and NF-kB signaling pathway has been described previously in macrophages isolated from patients with atherosclerosis. In those patients, and in contrast with our results,[5]\"\n",
    "item9 = \"Niclosamide and derivatives - potent inhibitors of TMEM16A/F and Ca2+ signaling. NFA is a nonsteroidal anti-inflammatory compound that inhibits goblet cell degranulation and suppresses asthma phenotype (4, 27). ...This result suggests an antiinflammatory effect of niclosamide, which corresponds well to inhibition of allergic lung inflammation by the TMEM16A inhibitor benzbromarone (3, 31).[6]\"\n",
    "item10 = \"The key findings of this study are that (a) Cl- fluxes mediated by the Ca2+gated channel TMEM16A are a crucial determinant of pericyte tone; (b) TMEM16A is activated during ischemia and evokes a long-lasting pericytemediated capillary constriction that reduces CBF and favors neutrophil and platelet stalling; (c) genetic analysis suggests that increased TMEM16A expression is associated with poor recovery after ischemic stroke (and the genetic proxy[7]\"\n",
    "\n",
    "item11 = \"Role of NOTCH3 Mutations in the Cerebral Small Vessel Disease Cerebral Autosomal Dominant Arteriopathy ... (Stroke 2018). There is currently no consensus on whether CADASIL mutations generate hyperactive or hypoactive Notch3 proteins with ...[1]\"\n",
    "item12 = \"Differences in proliferation rate between CADASIL and control vascular smooth muscle cells are ... (J Cell Mol Med 2018). We believe that increased TGFb3 reflects an inflammatory condition and even an involvement of TGFb in fibrosis in CADASIL. ... showed NOTCH3 and TGFb1 signalling play a key role in the pathogenesis and progression of chronic...[2]\"\n",
    "item13 = \"The Role of Vascular Smooth Muscle Cells in Arterial Remodeling: Focus on Calcification ... (Int J Mol Sci 2019). Over time, VSMCs apoptosis leads to fibrosis and thickening of the arterial wall, progressive lumen stenosis and vascular insufficiency that makes the already poorly perfused ...[3]\"\n",
    "item14 = \"Spleen Tyrosine Kinase (SYK) in the Progression of Peritoneal Fibrosis Through Activation of the ... (Med Sci Monit 2019). Previously published studies have shown that TGF-b signaling is closely associated with the activity of SYK, and the kinase ...[4]\"\n",
    "item15 = \"NOTCH3 signaling is essential for NF-kB activation in TLRactivated macrophages (Sci Rep 2020). Our work confirms and highlights the relevance of NOTCH3 expression and signaling in pro-inflammatory macrophage ...[5]\"\n",
    "item16 = \"Niclosamide repurposed for the treatment of inflammatory airway disease (JCI Insight 2019). Niclosamide and derivatives - potent inhibitors of TMEM16A/F and Ca2+ signaling. NFA is a nonsteroidal antiinflammatory compound that inhibits goblet ...[6]\"\n",
    "item17 = \"The Ca2+-gated channel TMEM16A amplifies capillary pericyte contraction and reduces ... (J Clin Invest. 2022). The key findings of this study are that (a) Cl- fluxes mediated by the Ca2+-gated channel TMEM16A are a crucial determinant of pericyte tone[7]\"\n",
    "\n",
    "gt1 = \"CADASIL is a rare hereditary cerebrovascular disease caused by a NOTCH3 mutation[1][2]. NOTCH3 is particularly important for the maturation of vascular smooth muscle cells (VSMCs). A decreased VSMC is a pathological hallmark for CADASIL[3].\"\n",
    "gt2 = \"Syk is a therapeutic target for CADASIL. In CADASIL, proinflammatory signaling is activated[1] through the increase of TGFb1 signaling[2]. The apoptosis of vascular smooth muscle cell (VSMC) and increased TGFb1 signaling cause fibrosis and vascular abnormalities in vascular epithelial cells[3]. Syk increases fibrosis through activation of TGFb1 signaling[4].\"\n",
    "gt3 = \"TMEM16A is a therapeutic target for CADASIL. Ischemia in CADASIL activates TMEM16A, Ca2+ gated Cl- channel, which regulates pericyte tone and induces capillary constriction[1]. Potent inhibitors of TMEM16A, niclosamide has antiinflammtory effect[2]. Niclosamide can suppress enhance inflammation in CADASIL[3].\"\n",
    "gt4 = \"Syk is a therapeutic target for CADASIL. In CADASIL, proinflammatory signaling is activated[1] through the increase of TGFb1 signaling[2] . The apoptosis of vascular smooth muscle cell (VSMC) and increased TGFb1 signaling cause fibrosis and vascular abnormalities in vascular epithelial cells[3] . Syk increases fibrosis through activation of TGFb1 signaling[4].\"\n",
    "gt5 = \"TMEM16A is a therapeutic target for CADASIL. Ischemia in CADASIL activates TMEM16A, Ca2+ gated Cl- channel, which regulates pericyte tone and induces capillary constriction[1]. Potent inhibitors of TMEM16A, niclosamide has antiinflammtory effect[2]. Niclosamide can suppress enhance inflammation in CADASIL[3].\"\n",
    "\n",
    "q1 = \"What is the cause of the CADASIL?\"\n",
    "q2 = \"What is the therapeutic target for CADASIL?\"\n",
    "q3 = \"What is the therapeutic target for CADASIL?\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [],
   "source": [
    "## 현재님께서 retrieve하신 evidences\n",
    "\n",
    "rt_item1 = \"CADASIL) is sometimes misdiagnosed as multiple sclerosis (MS). MS and CADASIL are not known to co-occur and brain magnetic resonance imagining (MRI) findings can help with differential diagnosis. Despite the availability of this information, a case report is presented of a 61-year-old woman who was misdiagnosed with MS at age 50, tested positive for CADASIL at age 56, described incorrectly as having both conditions simultaneously, and continued on MS disease-modifying medications, resulting in financial and physical hardship.[1]\"\n",
    "rt_item2 = \"Despite the availability of this information, a case report is presented of a 61-year-old woman who was misdiagnosed with MS at age 50, tested positive for CADASIL at age 56, described incorrectly as having both conditions simultaneously, and continued on MS disease-modifying medications, resulting in financial and physical hardship. Neuropsychological consultation helped initiate removal of the MS diagnosis and treatment. Better understanding is needed among clinicians that MS and CADASIL are not known to co-exist, that no association has been found between MS and the NOTCH3 mutations that cause CADASIL, and that neuroimaging and clinical features can help distinguish between the two conditions in addition to genetic testing.[2]\"\n",
    "rt_item3 = \"Antithrombotic drugs were used in three patients, in one for an unrelated coexisting prothrombotic condition. CADASIL does not seem to be associated with an unfavorable outcome of pregnancy either for women and fetuses. Patients and treating physicians should be reassured that pregnancy can be safely initiated in CADASIL, as there is no evidence to support a specific preventive antithrombotic treatment during pregnancy in CADASIL.[3]\"\n",
    "\n",
    "rt_item4 = \"Using both wild type mice and transgenic mice carrying the human mutant Notch3 gene (CADASIL mice), we have recently characterized the pathological features of CADASIL and determined the therapeutic efficacy of two hematopoietic growth factors, stem cell factor (SCF) and granulocyte colony-stimulating factor (G-CSF) in CADASIL. Our findings have revealed novel pathological changes in the endothelium of cerebral capillaries and in the neural stem cells (NSCs). We have also observed the impairment of cognitive function in CADASIL mice.[1]\"\n",
    "rt_item5 = \"Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common condition of hereditary stroke and vascular dementia. CADASIL is caused by Notch3 mutation, leading to progressive degeneration of vascular smooth muscle cells (VSMCs) of the small arteries in the brain. However, the pathogenesis of CADASIL remains largely unknown, and treatment that can stop or delay the progression of CADASIL is not yet available.[2]\"\n",
    "rt_item6 = \"Today, CADASIL is known to every neurologist, but the disease has not yet revealed all its secrets. A lot of effort is still needed to understand the intimate mechanisms of the disease and the most efficient targets or approaches for the development of efficient therapeutics. The history of CADASIL will be further enriched by multiple ongoing research projects worldwide, at clinical and preclinical level, and will continue to enlighten research in the field of cerebral small vessel disorders.[3]\"\n",
    "\n",
    "rt_item7 = \"Syk inhibition was found to stabilize microtubules and potentiate paclitaxel activity in cellular models of taxane-resistant ovarian cancers. We further studied the effects of Syk inhibition on paclitaxel activity in Syk(+) ovarian cancer cell models and in variants selected for taxane resistance. Syk inhibition was accomplished using RNAi and by exposure to the small molecule competitive inhibitor R406, the active metabolite of fostamatinib.[1]\"\n",
    "rt_item8 = \"Therefore, inhibition of the inflammatory macrophages would be a promising approach to attenuate NASH. In this study, we studied the implication of SYK pathway in NASH, and investigated PLGA nanoparticles-based delivery of SYK pathway inhibitor as an effective and promising therapeutic approach for the treatment of NASH. We found positive correlation between SYK expression with the pathogenesis of NASH and alcoholic hepatitis in patients.[2]\"\n",
    "rt_item9 = \"Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common condition of hereditary stroke and vascular dementia. CADASIL is caused by Notch3 mutation, leading to progressive degeneration of vascular smooth muscle cells (VSMCs) of the small arteries in the brain. However, the pathogenesis of CADASIL remains largely unknown, and treatment that can stop or delay the progression of CADASIL is not yet available.[3]\"\n",
    "\n",
    "\n",
    "rt_q1 = \"can nilvadipine help alleviate cadasil symptoms?\"\n",
    "rt_q2 = \"what are the potential therapeutic targets for cadasil?\"\n",
    "rt_q3 = \"would SYK inhibition be potential treatment for cadasil?\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "## dic['data'] = list of dictionaries. each dic has fields: \"query\", \"evidences\"(itself a list of strings), \"ground_truth\"\n",
    "## pre-compute data dictionary file. yea? yep. \n",
    "## see how the code handles cases without ground truth -> from same example dic, just doesn't take the ground truth. \n",
    "## make three with complete examples, three with retrieved evidences, \n",
    "## or make two json files one with the three complete examples and the other with retrieved evidences. \n",
    "\n",
    "import json\n",
    "\n",
    "context1 = {\"query\": q1, \"evidences\": [item1, item2, item3], \"ground_truth\": gt1}\n",
    "\n",
    "context2 = {\"query\": q2, \"evidences\": [item4, item5, item6, item7, item8], \"ground_truth\": gt2}\n",
    "context3 = {\"query\": q2, \"evidences\": [item4, item8, item9, item10], \"ground_truth\": gt3}\n",
    "\n",
    "context4 = {\"query\": q3, \"evidences\": [item11, item12, item13, item14, item15], \"ground_truth\": gt4}\n",
    "context5 = {\"query\": q3, \"evidences\": [item11, item15, item16, item17], \"ground_truth\": gt5}\n",
    "\n",
    "query1 = {\"query\": rt_q1, \"evidences\": [rt_item1, rt_item2, rt_item3]}\n",
    "query2 = {\"query\": rt_q2, \"evidences\": [rt_item4, rt_item5, rt_item6]}\n",
    "query3 = {\"query\": rt_q3, \"evidences\": [rt_item7, rt_item8, rt_item9]}\n",
    "\n",
    "dic = {'contexts': [context1, context2, context3, context4, context5], 'queries': [query1, query2, query3]}\n",
    "\n",
    "with open(\"examples_20230207.json\", \"w\") as outfile:\n",
    "    json.dump(dic, outfile)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "with open('examples_20230207.json') as f:\n",
    "    loaded_dic = json.load(f)\n",
    "    contexts = loaded_dic['contexts']\n",
    "    queries = loaded_dic['queries']\n",
    "    \n",
    "    \n",
    "## any combination of contexts[i] and queries[i] possible? -> well contexts can be query but not the other way around\n",
    "# also, context 23 and 45 are v similar\n",
    "\n",
    "args = [(contexts[0], contexts[1]), (contexts[0], contexts[2]), (contexts[0], contexts[3]), (contexts[0], contexts[4]),\\\n",
    "        (contexts[1], contexts[0]), (contexts[2], contexts[0]), (contexts[3], contexts[0]), (contexts[4], contexts[0]),\\\n",
    "        (contexts[1], contexts[2]), (contexts[2], contexts[1]),\\\n",
    "        (contexts[3], contexts[4]), (contexts[4], contexts[3]),\\\n",
    "        (contexts[0], queries[0]), (contexts[1], queries[0]), (contexts[2], queries[0]),\\\n",
    "        (contexts[0], queries[1]), (contexts[1], queries[1]), (contexts[2], queries[1]),\\\n",
    "        (contexts[0], queries[2]), (contexts[1], queries[2]), (contexts[2], queries[2])]\n",
    "\n",
    "args = []\n",
    "for i, c1 in enumerate(contexts):\n",
    "    for j, c2 in enumerate(contexts):\n",
    "        if i != j:\n",
    "            args.append((c1, c2))\n",
    "    for q in queries:\n",
    "        args.append((c1, q))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "def make_prompt(example, query, zeroshot=False): # both args are of type either context dic or query dic -> {\"query\": q3, \"evidences\": [item11, item15, item16, item17], \"ground_truth\": gt5}\n",
    "    \n",
    "    example_part = \"\"\n",
    "    if not zeroshot:\n",
    "        for i, ev in enumerate(example['evidences']):\n",
    "            example_part += f\"evidence {i}: {ev} \\n\"\n",
    "\n",
    "        example_part += f\"query: {example['query']} \\n\"\n",
    "        example_part += \"summarize given evidences and query:\"\n",
    "        example_part += f\"{example['ground_truth']} \\n\\n\"\n",
    "    \n",
    "    query_part = \"\"\n",
    "    for i, ev in enumerate(query['evidences']):\n",
    "        query_part += f\"evidence {i}: {ev} \\n\"\n",
    "    \n",
    "    query_part += f\"query: {query['query']} \\n\"\n",
    "    query_part += \"summarize given evidences and query:\"\n",
    "    \n",
    "    prompt =  example_part + query_part\n",
    "    return prompt\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "ename": "AttributeError",
     "evalue": "'PegasusTokenizerFast' object has no attribute 'to'",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mAttributeError\u001b[0m                            Traceback (most recent call last)",
      "Input \u001b[0;32mIn [10]\u001b[0m, in \u001b[0;36m<cell line: 1>\u001b[0;34m()\u001b[0m\n\u001b[0;32m----> 1\u001b[0m \u001b[43mtokenizer\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mto\u001b[49m(device)\n",
      "\u001b[0;31mAttributeError\u001b[0m: 'PegasusTokenizerFast' object has no attribute 'to'"
     ]
    }
   ],
   "source": [
    "tokenizer.to(device)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "item1 = '''Here we report the characterization of the human Notch3 gene which we mapped to the CADASIL critical region. We have identified mutations in CADASIL patients that cause serious disruption of this gene, indicating that Notch3 could be the defective protein in CADASIL patients. All these missense mutations may result in severe disruption of the Notch3 protein, as suggested by the highly conserved nature of the aminoacid residues involved, particularly the cysteines that are key features of EGF likedomains24. These results indicate that these nucleotide substitutions are pathogenic mutations rather than rare polymorphisms.'''\n",
    "item2 = '''Linkage studies in other families enabled further refinement of this genetic interval16,17 and identification of the mutated gene as NOTCH3 (Notch homolog 3).18'''\n",
    "item3 = '''CADASIL, a hereditary vascular dementia, suggesting a role for Notch3 in vessel homeostasis (Joutel et al. 1996). CADASIL is a late-onset disorder, and neurological symptoms arise from a slowly developing systemic vasculopathy, characterized ultimately by degeneration of vSMC . maturation of vSMC, and ends around P28 when the artery acquires its final shape. We identify Notch3 to be the first key player of this process, by regulating cell-autonomously the arterial differentiation and maturation of vSMC.'''\n",
    "\n",
    "item3 = \"There is currently no consensus on whether CADASIL mutations generate hyperactive or hypoactive Notch3 proteins with regard to downstream signaling or whether CADASIL mutations are neutral in terms of Notch signaling. Whereas the R169C mutation appeared to lead to hyperactive Notch signaling (see above), the R1031C or C455R mutations were instead shown to be hypoactive,36 \"\n",
    "item4 = \"We believe that increased TGFb3 reflects an inflammatory condition and even an involvement of TGFb in fibrosis in CADASIL. Support for our hypothesis is the outcome of several studies that showed NOTCH3 and TGFb1 signalling play a key role in the pathogenesis and progression of chronic cardiovascular disease. \"\n",
    "item5 = \"Over time, VSMCs apoptosis leads to fibrosis and thickening of the arterial wall, progressive lumen stenosis and vascular insufficiency that makes the already poorly perfused terminal regions particularly susceptible to infarcts. SMCs degeneration is followed by the emergence of large\"\n",
    "item6 = \"Previously published studies have shown that TGF-b signaling is closely associated with the activity of SYK, and the kinase activity of SYK is essential for the activation of some signaling receptor downstream effector molecules. In the present study, the activation of SYK was shown to increase the progression of peritoneal fibrosis through activation of the TGF-b1/Smad3 signaling pathway, and inhibition of TGF-b1 also resulted in down-regulation of SYK.\"\n",
    "item7 = \"Our work confirms and highlights the relevance of NOTCH3 expression and signaling in pro-inflammatory macrophage activation and identified its prominent and specific role in the activation of NF-κB. A positive regulation between NOTCH and NF-κB signaling pathway has been described previously in macrophages isolated from patients with atherosclerosis. In those patients, and in contrast with our results, \"\n",
    "\n",
    "gt = \"Syk is a therapeutic target for CADASIL. In CADASIL, proinflammatory signaling is activated through the increase of TGFb1 signaling. The apoptosis of vascular smooth muscle cell (VSMC) and increased TGFb1 signaling cause fibrosis and vascular abnormalities in vascular epithelial cells. Syk increases fibrosis through activation of TGF-b1 signaling.\"\n",
    "\n",
    "set1 = {\"query\": 'What is the cause of the CADASIL?', \"evidences\": [item1, item2, item3]}\n",
    "set2 = {\"query\": 'What is the therapeutic target for CADASIL?', \"evidences\": [item3, item4, item5, item6, item7], \"ground_truth\": gt}\n",
    "\n",
    "args = (set2, set1)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "< PROMPT >\n",
      "\n",
      "evidence 0: Here we report the characterization of the human Notch3 gene which we mapped to the CADASIL critical region. We have identified mutations in CADASIL patients that cause serious disruption of this gene, indicating that Notch3 could be the defective protein in CADASIL patients.All these missense mutations may result in severe disruption of the Notch3 protein, as suggested by the highly conserved nature of the aminoacid residues involved, particularly the cysteines that are key features of EGF likedomains24. These results indicate that these nucleotide substitutions are pathogenic mutations rather than rare polymorphisms.[1] \n",
      "evidence 1: Linkage studies in other families enabled further refinement of this genetic interval16,17 and identification of the mutated gene as NOTCH3 (Notch homolog 3).18[2] \n",
      "evidence 2: CADASIL, a hereditary vascular dementia, suggesting a role for Notch3 in vessel homeostasis (Joutel et al. 1996). CADASIL is a late-onset disorder, and neurological symptoms arise from a slowly developing systemic vasculopathy, characterized ultimately by degeneration of VSMC. ...maturation of VSMC, and ends around P28 when the artery acquires its final shape. We identify Notch3 to be the first key player of this process, by regulating cell-autonomously the arterial differentiation and maturation of VSMC.[3] \n",
      "query: What is the cause of the CADASIL? \n",
      "summarize given evidences and query:CADASIL is a rare hereditary cerebrovascular disease caused by a NOTCH3 mutation[1][2]. NOTCH3 is particularly important for the maturation of vascular smooth muscle cells (VSMCs). A decreased VSMC is a pathological hallmark for CADASIL[3]. \n",
      "\n",
      "evidence 0: There is currently no consensus on whether CADASIL mutations generate hyperactive or hypoactive Notch3 proteins with regard to downstream signaling or whether CADASIL mutations are neutral in terms of Notch signaling. Whereas the R169C mutation appeared to lead to hyperactive Notch signaling (see above), the R1031C or C455R mutations were instead shown to be hypoactive,36[1] \n",
      "evidence 1: We believe that increased TGFb3 reflects an inflammatory condition and even an involvement of TGFb in fibrosis in CADASIL. Support for our hypothesis is the outcome of several studies that showed NOTCH3 and TGFb1 signalling play a key role in the pathogenesis and progression of chronic cardiovascular disease.[2] \n",
      "evidence 2: Over time, VSMCs apoptosis leads to fibrosis and thickening of the arterial wall, progressive lumen stenosis and vascular insufficiency that makes the already poorly perfused terminal regions particularly susceptible to infarcts. SMCs degeneration is followed by the emergence of large,...[3] \n",
      "evidence 3: Previously published studies have shown that TGF-b signaling is closely associated with the activity of SYK, and the kinase activity of SYK is essential for the activation of some signaling receptor downstream effector molecules[25]. ...bidirectional[33]. In the present study, the activation of SYK was shown to increase the progression of peritoneal fibrosis through activation of the TGF-b1/Smad3 signaling pathway, and inhibition of TGF-b1 also resulted in down-regulation of SYK.[4] \n",
      "evidence 4: Our work confirms and highlights the relevance of NOTCH3 expression and signaling in pro-inflammatory macrophage activation and identified its prominent and specific role in the activation of NF-kB. A positive regulation between NOTCH and NF-kB signaling pathway has been described previously in macrophages isolated from patients with atherosclerosis. In those patients, and in contrast with our results,[5] \n",
      "query: What is the therapeutic target for CADASIL? \n",
      "summarize given evidences and query:\n",
      "\n",
      "\n",
      "< GENERATED >\n",
      "\n",
      "['we report characterization of human3 gene in which we mapped mutations in patients that cause : ( i ) severe : ( ii ) disruption of : ( iii ) proinflammatory signaling : ( iv ) aminoacid residues : ( v ) cysteines : ( vi ) serine / threonine : ( vii ) serine / threonine : ( viii ) serine / threonine : ( ix ) serine / threonine : ( viii ) cysteines : ( ix ) serine / threonine : ( ix ) serine / threonine : ( ix ) serine / threonine : ( ix ) serine / threonine : ( ix ) cysteines : ( ix ) serine / threonine : ( ix ) serine / threonine : ( ix ) cysteines : ( ix ) serine / threonine : ( ix ) serine / threonine : ( ix ) serine / threonine : ( ix ) serine / threonine : ( ix ) serine / threonine : ( ix ) serine / threonine : ( ix ) serine / threonine : ( ix ) serine / threonine : ( ix : ( ix ) serine / threonine : ( ix : ( ix )']\n",
      "\n",
      "###############################################################################################################################################################\n",
      "\n",
      "< PROMPT >\n",
      "\n",
      "evidence 0: Here we report the characterization of the human Notch3 gene which we mapped to the CADASIL critical region. We have identified mutations in CADASIL patients that cause serious disruption of this gene, indicating that Notch3 could be the defective protein in CADASIL patients.All these missense mutations may result in severe disruption of the Notch3 protein, as suggested by the highly conserved nature of the aminoacid residues involved, particularly the cysteines that are key features of EGF likedomains24. These results indicate that these nucleotide substitutions are pathogenic mutations rather than rare polymorphisms.[1] \n",
      "evidence 1: Linkage studies in other families enabled further refinement of this genetic interval16,17 and identification of the mutated gene as NOTCH3 (Notch homolog 3).18[2] \n",
      "evidence 2: CADASIL, a hereditary vascular dementia, suggesting a role for Notch3 in vessel homeostasis (Joutel et al. 1996). CADASIL is a late-onset disorder, and neurological symptoms arise from a slowly developing systemic vasculopathy, characterized ultimately by degeneration of VSMC. ...maturation of VSMC, and ends around P28 when the artery acquires its final shape. We identify Notch3 to be the first key player of this process, by regulating cell-autonomously the arterial differentiation and maturation of VSMC.[3] \n",
      "query: What is the cause of the CADASIL? \n",
      "summarize given evidences and query:CADASIL is a rare hereditary cerebrovascular disease caused by a NOTCH3 mutation[1][2]. NOTCH3 is particularly important for the maturation of vascular smooth muscle cells (VSMCs). A decreased VSMC is a pathological hallmark for CADASIL[3]. \n",
      "\n",
      "evidence 0: There is currently no consensus on whether CADASIL mutations generate hyperactive or hypoactive Notch3 proteins with regard to downstream signaling or whether CADASIL mutations are neutral in terms of Notch signaling. Whereas the R169C mutation appeared to lead to hyperactive Notch signaling (see above), the R1031C or C455R mutations were instead shown to be hypoactive,36[1] \n",
      "evidence 1: Our work confirms and highlights the relevance of NOTCH3 expression and signaling in pro-inflammatory macrophage activation and identified its prominent and specific role in the activation of NF-kB. A positive regulation between NOTCH and NF-kB signaling pathway has been described previously in macrophages isolated from patients with atherosclerosis. In those patients, and in contrast with our results,[5] \n",
      "evidence 2: Niclosamide and derivatives - potent inhibitors of TMEM16A/F and Ca2+ signaling. NFA is a nonsteroidal anti-inflammatory compound that inhibits goblet cell degranulation and suppresses asthma phenotype (4, 27). ...This result suggests an antiinflammatory effect of niclosamide, which corresponds well to inhibition of allergic lung inflammation by the TMEM16A inhibitor benzbromarone (3, 31).[6] \n",
      "evidence 3: The key findings of this study are that (a) Cl- fluxes mediated by the Ca2+gated channel TMEM16A are a crucial determinant of pericyte tone; (b) TMEM16A is activated during ischemia and evokes a long-lasting pericytemediated capillary constriction that reduces CBF and favors neutrophil and platelet stalling; (c) genetic analysis suggests that increased TMEM16A expression is associated with poor recovery after ischemic stroke (and the genetic proxy[7] \n",
      "query: What is the therapeutic target for CADASIL? \n",
      "summarize given evidences and query:\n",
      "\n",
      "\n",
      "< GENERATED >\n",
      "\n",
      "['key clinical messagewe report characterization of human3 gene, which we mapped patients have identified mutations in, that cause serious disruption of : ( 1 ) protein : ( 2 ) aminodomains : ( 3 ) cysteine residues : ( 4 ) aminoacid residues : ( 5 ) stroke residues : ( 6 ) other nucleotides : ( 7 ) rare polymorphisms : ( 8) evidence of pathogenic mutations in : ( 9 ) family : ( 10 ) other families : ( 11 ) gene : ( 12 ) gene : ( 13 ) gene : ( 14 ) gene : ( 15 ) gene : ( 16 ) gene : ( 17 ) gene : ( 18 ) gene : ( 19 )']\n",
      "\n",
      "###############################################################################################################################################################\n",
      "\n",
      "< PROMPT >\n",
      "\n",
      "evidence 0: Here we report the characterization of the human Notch3 gene which we mapped to the CADASIL critical region. We have identified mutations in CADASIL patients that cause serious disruption of this gene, indicating that Notch3 could be the defective protein in CADASIL patients.All these missense mutations may result in severe disruption of the Notch3 protein, as suggested by the highly conserved nature of the aminoacid residues involved, particularly the cysteines that are key features of EGF likedomains24. These results indicate that these nucleotide substitutions are pathogenic mutations rather than rare polymorphisms.[1] \n",
      "evidence 1: Linkage studies in other families enabled further refinement of this genetic interval16,17 and identification of the mutated gene as NOTCH3 (Notch homolog 3).18[2] \n",
      "evidence 2: CADASIL, a hereditary vascular dementia, suggesting a role for Notch3 in vessel homeostasis (Joutel et al. 1996). CADASIL is a late-onset disorder, and neurological symptoms arise from a slowly developing systemic vasculopathy, characterized ultimately by degeneration of VSMC. ...maturation of VSMC, and ends around P28 when the artery acquires its final shape. We identify Notch3 to be the first key player of this process, by regulating cell-autonomously the arterial differentiation and maturation of VSMC.[3] \n",
      "query: What is the cause of the CADASIL? \n",
      "summarize given evidences and query:CADASIL is a rare hereditary cerebrovascular disease caused by a NOTCH3 mutation[1][2]. NOTCH3 is particularly important for the maturation of vascular smooth muscle cells (VSMCs). A decreased VSMC is a pathological hallmark for CADASIL[3]. \n",
      "\n",
      "evidence 0: Role of NOTCH3 Mutations in the Cerebral Small Vessel Disease Cerebral Autosomal Dominant Arteriopathy ... (Stroke 2018). There is currently no consensus on whether CADASIL mutations generate hyperactive or hypoactive Notch3 proteins with ...[1] \n",
      "evidence 1: Differences in proliferation rate between CADASIL and control vascular smooth muscle cells are ... (J Cell Mol Med 2018). We believe that increased TGFb3 reflects an inflammatory condition and even an involvement of TGFb in fibrosis in CADASIL. ... showed NOTCH3 and TGFb1 signalling play a key role in the pathogenesis and progression of chronic...[2] \n",
      "evidence 2: The Role of Vascular Smooth Muscle Cells in Arterial Remodeling: Focus on Calcification ... (Int J Mol Sci 2019). Over time, VSMCs apoptosis leads to fibrosis and thickening of the arterial wall, progressive lumen stenosis and vascular insufficiency that makes the already poorly perfused ...[3] \n",
      "evidence 3: Spleen Tyrosine Kinase (SYK) in the Progression of Peritoneal Fibrosis Through Activation of the ... (Med Sci Monit 2019). Previously published studies have shown that TGF-b signaling is closely associated with the activity of SYK, and the kinase ...[4] \n",
      "evidence 4: NOTCH3 signaling is essential for NF-kB activation in TLRactivated macrophages (Sci Rep 2020). Our work confirms and highlights the relevance of NOTCH3 expression and signaling in pro-inflammatory macrophage ...[5] \n",
      "query: What is the therapeutic target for CADASIL? \n",
      "summarize given evidences and query:\n",
      "\n",
      "\n",
      "< GENERATED >\n",
      "\n",
      "['evidence 0: evidence 0: we report characterization of human gene3 [ 1 ] : we report characterization of human gene3 [ 2 ] : we report characterization of human gene3 [ 3 ] : we report characterization of human gene3 [ 4 ] : we report characterization of human gene3 [ 5 ] : we report characterization of human gene3 [ 6 ] : we report characterization of human gene3 [ 7 ] : we report characterization of human gene3 [ 8 ] : we report characterization of human gene3 [ 9 ] : we report characterization of human gene3 [ 10 ] : we report characterization of human gene3 [ 11 ] : we report characterization of human gene3 [ 12 ] : we report characterization of human gene3 [ 13 ] : we report characterization of human gene3 [ 14 ] : we report characterization of human gene3 [ 15 ] : we report characterization of human gene3 [ 16 ] : we report characterization of human gene3 [ 17 ] : we report characterization of human gene3 [ 18 ] : we report characterization of human gene3 [ 19 ] : we report characterization of human gene3 [ 20 ] : we report characterization of human gene3 [ 21 ] : we report characterization of human gene3 [ 22 ] : we report characterization of human gene3 [ 23 ] : we report characterization of human gene3 [ 24 : we report : we report characterization of human gene3 [ 25 ]. evidence 0: evidence 0 : evidence 0: evidence 0: evidence : evidence 0: evidence 0: evidence. evidence 0: evidence 0: evidence ( the loss of the expression of gene3 [ 1 ). evidence. evidence. evidence 0 : evidence 0: evidence 0: evidence : evidence 0: evidence 0: evidence ( the loss of the loss of the ability of the ability of the ability of the ability of gene 3 ( the ability of gene [ 3. [ 3. the gene [ 3]. evidence. evidence 0. evidence. the influence on the effects on the effects on vascular wall formation of vascular maturation and the effects ( vascular maturation [ 3..']\n",
      "\n",
      "###############################################################################################################################################################\n",
      "\n",
      "< PROMPT >\n",
      "\n",
      "evidence 0: Here we report the characterization of the human Notch3 gene which we mapped to the CADASIL critical region. We have identified mutations in CADASIL patients that cause serious disruption of this gene, indicating that Notch3 could be the defective protein in CADASIL patients.All these missense mutations may result in severe disruption of the Notch3 protein, as suggested by the highly conserved nature of the aminoacid residues involved, particularly the cysteines that are key features of EGF likedomains24. These results indicate that these nucleotide substitutions are pathogenic mutations rather than rare polymorphisms.[1] \n",
      "evidence 1: Linkage studies in other families enabled further refinement of this genetic interval16,17 and identification of the mutated gene as NOTCH3 (Notch homolog 3).18[2] \n",
      "evidence 2: CADASIL, a hereditary vascular dementia, suggesting a role for Notch3 in vessel homeostasis (Joutel et al. 1996). CADASIL is a late-onset disorder, and neurological symptoms arise from a slowly developing systemic vasculopathy, characterized ultimately by degeneration of VSMC. ...maturation of VSMC, and ends around P28 when the artery acquires its final shape. We identify Notch3 to be the first key player of this process, by regulating cell-autonomously the arterial differentiation and maturation of VSMC.[3] \n",
      "query: What is the cause of the CADASIL? \n",
      "summarize given evidences and query:CADASIL is a rare hereditary cerebrovascular disease caused by a NOTCH3 mutation[1][2]. NOTCH3 is particularly important for the maturation of vascular smooth muscle cells (VSMCs). A decreased VSMC is a pathological hallmark for CADASIL[3]. \n",
      "\n",
      "evidence 0: Role of NOTCH3 Mutations in the Cerebral Small Vessel Disease Cerebral Autosomal Dominant Arteriopathy ... (Stroke 2018). There is currently no consensus on whether CADASIL mutations generate hyperactive or hypoactive Notch3 proteins with ...[1] \n",
      "evidence 1: NOTCH3 signaling is essential for NF-kB activation in TLRactivated macrophages (Sci Rep 2020). Our work confirms and highlights the relevance of NOTCH3 expression and signaling in pro-inflammatory macrophage ...[5] \n",
      "evidence 2: Niclosamide repurposed for the treatment of inflammatory airway disease (JCI Insight 2019). Niclosamide and derivatives - potent inhibitors of TMEM16A/F and Ca2+ signaling. NFA is a nonsteroidal antiinflammatory compound that inhibits goblet ...[6] \n",
      "evidence 3: The Ca2+-gated channel TMEM16A amplifies capillary pericyte contraction and reduces ... (J Clin Invest. 2022). The key findings of this study are that (a) Cl- fluxes mediated by the Ca2+-gated channel TMEM16A are a crucial determinant of pericyte tone[7] \n",
      "query: What is the therapeutic target for CADASIL? \n",
      "summarize given evidences and query:\n",
      "\n",
      "\n",
      "< GENERATED >\n",
      "\n",
      "['evidence 0: we report characterization of human3 gene, which we mapped critical region, and identified mutations in patients. <n> evidence 0: we report characterization of human3 gene, which we mapped critical region, and identified mutations in patients. <n> evidence 0: we report characterization of human3 gene, which we mapped critical region, and identified mutations in patients. <n> evidence 0: we report characterization of human3 gene, which we mapped critical region, and identified mutations in patients. <n> evidence 0 : we report characterization of human3 gene, which we mapped critical region, and identified mutations in patients. <n> evidence 0 : we report characterization of human3 gene, which we mapped critical region, and identified mutations in patients. <n> evidence 0 : we report characterization of human3 gene, which we mapped critical region, and identified mutations in patients. <n> evidence 0 : we report characterization of human3 gene, which we mapped critical region, and identified mutations in patients.']\n",
      "\n",
      "###############################################################################################################################################################\n",
      "\n",
      "< PROMPT >\n",
      "\n",
      "evidence 0: There is currently no consensus on whether CADASIL mutations generate hyperactive or hypoactive Notch3 proteins with regard to downstream signaling or whether CADASIL mutations are neutral in terms of Notch signaling. Whereas the R169C mutation appeared to lead to hyperactive Notch signaling (see above), the R1031C or C455R mutations were instead shown to be hypoactive,36[1] \n",
      "evidence 1: We believe that increased TGFb3 reflects an inflammatory condition and even an involvement of TGFb in fibrosis in CADASIL. Support for our hypothesis is the outcome of several studies that showed NOTCH3 and TGFb1 signalling play a key role in the pathogenesis and progression of chronic cardiovascular disease.[2] \n",
      "evidence 2: Over time, VSMCs apoptosis leads to fibrosis and thickening of the arterial wall, progressive lumen stenosis and vascular insufficiency that makes the already poorly perfused terminal regions particularly susceptible to infarcts. SMCs degeneration is followed by the emergence of large,...[3] \n",
      "evidence 3: Previously published studies have shown that TGF-b signaling is closely associated with the activity of SYK, and the kinase activity of SYK is essential for the activation of some signaling receptor downstream effector molecules[25]. ...bidirectional[33]. In the present study, the activation of SYK was shown to increase the progression of peritoneal fibrosis through activation of the TGF-b1/Smad3 signaling pathway, and inhibition of TGF-b1 also resulted in down-regulation of SYK.[4] \n",
      "evidence 4: Our work confirms and highlights the relevance of NOTCH3 expression and signaling in pro-inflammatory macrophage activation and identified its prominent and specific role in the activation of NF-kB. A positive regulation between NOTCH and NF-kB signaling pathway has been described previously in macrophages isolated from patients with atherosclerosis. In those patients, and in contrast with our results,[5] \n",
      "query: What is the therapeutic target for CADASIL? \n",
      "summarize given evidences and query:Syk is a therapeutic target for CADASIL. In CADASIL, proinflammatory signaling is activated[1] through the increase of TGFb1 signaling[2]. The apoptosis of vascular smooth muscle cell (VSMC) and increased TGFb1 signaling cause fibrosis and vascular abnormalities in vascular epithelial cells[3]. Syk increases fibrosis through activation of TGFb1 signaling[4]. \n",
      "\n",
      "evidence 0: Here we report the characterization of the human Notch3 gene which we mapped to the CADASIL critical region. We have identified mutations in CADASIL patients that cause serious disruption of this gene, indicating that Notch3 could be the defective protein in CADASIL patients.All these missense mutations may result in severe disruption of the Notch3 protein, as suggested by the highly conserved nature of the aminoacid residues involved, particularly the cysteines that are key features of EGF likedomains24. These results indicate that these nucleotide substitutions are pathogenic mutations rather than rare polymorphisms.[1] \n",
      "evidence 1: Linkage studies in other families enabled further refinement of this genetic interval16,17 and identification of the mutated gene as NOTCH3 (Notch homolog 3).18[2] \n",
      "evidence 2: CADASIL, a hereditary vascular dementia, suggesting a role for Notch3 in vessel homeostasis (Joutel et al. 1996). CADASIL is a late-onset disorder, and neurological symptoms arise from a slowly developing systemic vasculopathy, characterized ultimately by degeneration of VSMC. ...maturation of VSMC, and ends around P28 when the artery acquires its final shape. We identify Notch3 to be the first key player of this process, by regulating cell-autonomously the arterial differentiation and maturation of VSMC.[3] \n",
      "query: What is the cause of the CADASIL? \n",
      "summarize given evidences and query:\n",
      "\n",
      "\n",
      "< GENERATED >\n",
      "\n",
      "['evidence 0: is currently consensus on whether rare mutations or hypoactive proteins are involved in the pathogenesis of cardiovascular disease ( cvd ). <n> evidence 0: is currently consensus on whether mutations or hypo3 + signaling proteins are involved in the pathogenesis of cvd. <n> evidence 0: is currently consensus on whether mutations or hypo3 + signaling proteins are involved in the pathogenesis of cvd. <n> evidence 0: is currently consensus on whether mutations or hypo3 + signaling proteins are involved in the pathogenesis of cvd. <n> evidence 0: is currently consensus on whether mutations or hypo3 + signaling proteins are involved in the pathogenesis of cvd. <n> evidence 0: is currently consensus on whether mutations or hypo3 + signaling proteins are involved in the pathogenesis of cvd. <n> evidence 0: is currently consensus on whether mutations or hypo3 + signaling proteins are involved in the pathogenesis of cvd. <n> evidence 0: is currently consensus on whether mutations or hypo3 + signaling proteins are involved in the pathogenesis of cvd. <n> evidence 0: is currently consensus on whether mutations or hypo3 + signaling proteins are involved in the pathogenesis of cvd. <n> evidence 0: is currently consensus on whether mutations or hypo3 + signaling proteins are involved in the pathogenesis of cvd.']\n",
      "\n",
      "###############################################################################################################################################################\n",
      "\n",
      "< PROMPT >\n",
      "\n",
      "evidence 0: There is currently no consensus on whether CADASIL mutations generate hyperactive or hypoactive Notch3 proteins with regard to downstream signaling or whether CADASIL mutations are neutral in terms of Notch signaling. Whereas the R169C mutation appeared to lead to hyperactive Notch signaling (see above), the R1031C or C455R mutations were instead shown to be hypoactive,36[1] \n",
      "evidence 1: Our work confirms and highlights the relevance of NOTCH3 expression and signaling in pro-inflammatory macrophage activation and identified its prominent and specific role in the activation of NF-kB. A positive regulation between NOTCH and NF-kB signaling pathway has been described previously in macrophages isolated from patients with atherosclerosis. In those patients, and in contrast with our results,[5] \n",
      "evidence 2: Niclosamide and derivatives - potent inhibitors of TMEM16A/F and Ca2+ signaling. NFA is a nonsteroidal anti-inflammatory compound that inhibits goblet cell degranulation and suppresses asthma phenotype (4, 27). ...This result suggests an antiinflammatory effect of niclosamide, which corresponds well to inhibition of allergic lung inflammation by the TMEM16A inhibitor benzbromarone (3, 31).[6] \n",
      "evidence 3: The key findings of this study are that (a) Cl- fluxes mediated by the Ca2+gated channel TMEM16A are a crucial determinant of pericyte tone; (b) TMEM16A is activated during ischemia and evokes a long-lasting pericytemediated capillary constriction that reduces CBF and favors neutrophil and platelet stalling; (c) genetic analysis suggests that increased TMEM16A expression is associated with poor recovery after ischemic stroke (and the genetic proxy[7] \n",
      "query: What is the therapeutic target for CADASIL? \n",
      "summarize given evidences and query:TMEM16A is a therapeutic target for CADASIL. Ischemia in CADASIL activates TMEM16A, Ca2+ gated Cl- channel, which regulates pericyte tone and induces capillary constriction[1]. Potent inhibitors of TMEM16A, niclosamide has antiinflammtory effect[2]. Niclosamide can suppress enhance inflammation in CADASIL[3]. \n",
      "\n",
      "evidence 0: Here we report the characterization of the human Notch3 gene which we mapped to the CADASIL critical region. We have identified mutations in CADASIL patients that cause serious disruption of this gene, indicating that Notch3 could be the defective protein in CADASIL patients.All these missense mutations may result in severe disruption of the Notch3 protein, as suggested by the highly conserved nature of the aminoacid residues involved, particularly the cysteines that are key features of EGF likedomains24. These results indicate that these nucleotide substitutions are pathogenic mutations rather than rare polymorphisms.[1] \n",
      "evidence 1: Linkage studies in other families enabled further refinement of this genetic interval16,17 and identification of the mutated gene as NOTCH3 (Notch homolog 3).18[2] \n",
      "evidence 2: CADASIL, a hereditary vascular dementia, suggesting a role for Notch3 in vessel homeostasis (Joutel et al. 1996). CADASIL is a late-onset disorder, and neurological symptoms arise from a slowly developing systemic vasculopathy, characterized ultimately by degeneration of VSMC. ...maturation of VSMC, and ends around P28 when the artery acquires its final shape. We identify Notch3 to be the first key player of this process, by regulating cell-autonomously the arterial differentiation and maturation of VSMC.[3] \n",
      "query: What is the cause of the CADASIL? \n",
      "summarize given evidences and query:\n",
      "\n",
      "\n",
      "< GENERATED >\n",
      "\n",
      "['in the last few years, there have been many advances in our understanding of the molecular mechanisms involved in the development of atherosclerosis. <n> one of these advances has been the identification of the key molecules involved in the activation of atherosclerotic plaques. in this article, we summarize the findings of that study.']\n",
      "\n",
      "###############################################################################################################################################################\n",
      "\n",
      "< PROMPT >\n",
      "\n",
      "evidence 0: Role of NOTCH3 Mutations in the Cerebral Small Vessel Disease Cerebral Autosomal Dominant Arteriopathy ... (Stroke 2018). There is currently no consensus on whether CADASIL mutations generate hyperactive or hypoactive Notch3 proteins with ...[1] \n",
      "evidence 1: Differences in proliferation rate between CADASIL and control vascular smooth muscle cells are ... (J Cell Mol Med 2018). We believe that increased TGFb3 reflects an inflammatory condition and even an involvement of TGFb in fibrosis in CADASIL. ... showed NOTCH3 and TGFb1 signalling play a key role in the pathogenesis and progression of chronic...[2] \n",
      "evidence 2: The Role of Vascular Smooth Muscle Cells in Arterial Remodeling: Focus on Calcification ... (Int J Mol Sci 2019). Over time, VSMCs apoptosis leads to fibrosis and thickening of the arterial wall, progressive lumen stenosis and vascular insufficiency that makes the already poorly perfused ...[3] \n",
      "evidence 3: Spleen Tyrosine Kinase (SYK) in the Progression of Peritoneal Fibrosis Through Activation of the ... (Med Sci Monit 2019). Previously published studies have shown that TGF-b signaling is closely associated with the activity of SYK, and the kinase ...[4] \n",
      "evidence 4: NOTCH3 signaling is essential for NF-kB activation in TLRactivated macrophages (Sci Rep 2020). Our work confirms and highlights the relevance of NOTCH3 expression and signaling in pro-inflammatory macrophage ...[5] \n",
      "query: What is the therapeutic target for CADASIL? \n",
      "summarize given evidences and query:Syk is a therapeutic target for CADASIL. In CADASIL, proinflammatory signaling is activated[1] through the increase of TGFb1 signaling[2] . The apoptosis of vascular smooth muscle cell (VSMC) and increased TGFb1 signaling cause fibrosis and vascular abnormalities in vascular epithelial cells[3] . Syk increases fibrosis through activation of TGFb1 signaling[4]. \n",
      "\n",
      "evidence 0: Here we report the characterization of the human Notch3 gene which we mapped to the CADASIL critical region. We have identified mutations in CADASIL patients that cause serious disruption of this gene, indicating that Notch3 could be the defective protein in CADASIL patients.All these missense mutations may result in severe disruption of the Notch3 protein, as suggested by the highly conserved nature of the aminoacid residues involved, particularly the cysteines that are key features of EGF likedomains24. These results indicate that these nucleotide substitutions are pathogenic mutations rather than rare polymorphisms.[1] \n",
      "evidence 1: Linkage studies in other families enabled further refinement of this genetic interval16,17 and identification of the mutated gene as NOTCH3 (Notch homolog 3).18[2] \n",
      "evidence 2: CADASIL, a hereditary vascular dementia, suggesting a role for Notch3 in vessel homeostasis (Joutel et al. 1996). CADASIL is a late-onset disorder, and neurological symptoms arise from a slowly developing systemic vasculopathy, characterized ultimately by degeneration of VSMC. ...maturation of VSMC, and ends around P28 when the artery acquires its final shape. We identify Notch3 to be the first key player of this process, by regulating cell-autonomously the arterial differentiation and maturation of VSMC.[3] \n",
      "query: What is the cause of the CADASIL? \n",
      "summarize given evidences and query:\n",
      "\n",
      "\n",
      "< GENERATED >\n",
      "\n",
      "['there is a growing body of evidence that vascular smooth muscle cells ( smcs ) play a critical role in the development of cardiovascular disease ( cvd ). <n> smcs are key cells of the vascular smooth muscle system ( vssms ), which is responsible for smooth muscle cell ( smc ) morphogenesis, blood vessel formation, smooth muscle cell ( smc ) apoptosis, endothelial cell ( ec ) proliferation, and smooth muscle cell ( smc ) migration. <n> we recently reported that smcs are involved in the development of atherosclerosis ( smc ). <n> in addition, we identified mutations in the gene encoding smc - related protein ( smcrp ). <n> smcrp is a member of the smc family of proteins, which includes smc1, smc2, smc3, smc4, smc5, smc6, smc7, smc8, smc9, smc10, smc11, smc12, smc13, smc14, smc15, smc16, smc17, smc18, smc19, and smc20. here, we summarize the evidence that smcrp plays a critical role in smc morphogenesis and atherosclerosis.']\n",
      "\n",
      "###############################################################################################################################################################\n",
      "\n",
      "< PROMPT >\n",
      "\n",
      "evidence 0: Role of NOTCH3 Mutations in the Cerebral Small Vessel Disease Cerebral Autosomal Dominant Arteriopathy ... (Stroke 2018). There is currently no consensus on whether CADASIL mutations generate hyperactive or hypoactive Notch3 proteins with ...[1] \n",
      "evidence 1: NOTCH3 signaling is essential for NF-kB activation in TLRactivated macrophages (Sci Rep 2020). Our work confirms and highlights the relevance of NOTCH3 expression and signaling in pro-inflammatory macrophage ...[5] \n",
      "evidence 2: Niclosamide repurposed for the treatment of inflammatory airway disease (JCI Insight 2019). Niclosamide and derivatives - potent inhibitors of TMEM16A/F and Ca2+ signaling. NFA is a nonsteroidal antiinflammatory compound that inhibits goblet ...[6] \n",
      "evidence 3: The Ca2+-gated channel TMEM16A amplifies capillary pericyte contraction and reduces ... (J Clin Invest. 2022). The key findings of this study are that (a) Cl- fluxes mediated by the Ca2+-gated channel TMEM16A are a crucial determinant of pericyte tone[7] \n",
      "query: What is the therapeutic target for CADASIL? \n",
      "summarize given evidences and query:TMEM16A is a therapeutic target for CADASIL. Ischemia in CADASIL activates TMEM16A, Ca2+ gated Cl- channel, which regulates pericyte tone and induces capillary constriction[1]. Potent inhibitors of TMEM16A, niclosamide has antiinflammtory effect[2]. Niclosamide can suppress enhance inflammation in CADASIL[3]. \n",
      "\n",
      "evidence 0: Here we report the characterization of the human Notch3 gene which we mapped to the CADASIL critical region. We have identified mutations in CADASIL patients that cause serious disruption of this gene, indicating that Notch3 could be the defective protein in CADASIL patients.All these missense mutations may result in severe disruption of the Notch3 protein, as suggested by the highly conserved nature of the aminoacid residues involved, particularly the cysteines that are key features of EGF likedomains24. These results indicate that these nucleotide substitutions are pathogenic mutations rather than rare polymorphisms.[1] \n",
      "evidence 1: Linkage studies in other families enabled further refinement of this genetic interval16,17 and identification of the mutated gene as NOTCH3 (Notch homolog 3).18[2] \n",
      "evidence 2: CADASIL, a hereditary vascular dementia, suggesting a role for Notch3 in vessel homeostasis (Joutel et al. 1996). CADASIL is a late-onset disorder, and neurological symptoms arise from a slowly developing systemic vasculopathy, characterized ultimately by degeneration of VSMC. ...maturation of VSMC, and ends around P28 when the artery acquires its final shape. We identify Notch3 to be the first key player of this process, by regulating cell-autonomously the arterial differentiation and maturation of VSMC.[3] \n",
      "query: What is the cause of the CADASIL? \n",
      "summarize given evidences and query:\n",
      "\n",
      "\n",
      "< GENERATED >\n",
      "\n",
      "[\"there is a lot of evidence to suggest that genetic factors play a role in the pathogenesis of many diseases. <n> for example, mutations in the gene coding for the transcription factor gata3 have been associated with familial alzheimer's disease ( fad ) and parkinson's disease ( pd ). <n> in contrast, mutations in the gene coding for g protein - coupled receptor ( gpcr ) have not been associated with fad or pd. <n> however, we recently reported that mutations in the gene coding for g protein - coupled receptor-2 ( gpcr2 ) have been associated with familial alzheimer's disease and parkinson's disease ( pd ). <n> in addition, we identified mutations in the gene coding for g protein - coupled receptor-4 ( gpcr4 ), which are associated with familial alzheimer's disease and pd, respectively. <n> thus, we identified mutations in the gene coding for gpcr2, gpcr4, g protein - coupled receptor-1 ( gpcr1 ), and g protein - coupled receptor-2 ( gpcr2 ), which are associated with familial alzheimer's disease and pd, respectively. <n> these findings suggest that genetic factors may play a role in the pathogenesis of fad and pd.\"]\n",
      "\n",
      "###############################################################################################################################################################\n",
      "\n",
      "< PROMPT >\n",
      "\n",
      "evidence 0: There is currently no consensus on whether CADASIL mutations generate hyperactive or hypoactive Notch3 proteins with regard to downstream signaling or whether CADASIL mutations are neutral in terms of Notch signaling. Whereas the R169C mutation appeared to lead to hyperactive Notch signaling (see above), the R1031C or C455R mutations were instead shown to be hypoactive,36[1] \n",
      "evidence 1: We believe that increased TGFb3 reflects an inflammatory condition and even an involvement of TGFb in fibrosis in CADASIL. Support for our hypothesis is the outcome of several studies that showed NOTCH3 and TGFb1 signalling play a key role in the pathogenesis and progression of chronic cardiovascular disease.[2] \n",
      "evidence 2: Over time, VSMCs apoptosis leads to fibrosis and thickening of the arterial wall, progressive lumen stenosis and vascular insufficiency that makes the already poorly perfused terminal regions particularly susceptible to infarcts. SMCs degeneration is followed by the emergence of large,...[3] \n",
      "evidence 3: Previously published studies have shown that TGF-b signaling is closely associated with the activity of SYK, and the kinase activity of SYK is essential for the activation of some signaling receptor downstream effector molecules[25]. ...bidirectional[33]. In the present study, the activation of SYK was shown to increase the progression of peritoneal fibrosis through activation of the TGF-b1/Smad3 signaling pathway, and inhibition of TGF-b1 also resulted in down-regulation of SYK.[4] \n",
      "evidence 4: Our work confirms and highlights the relevance of NOTCH3 expression and signaling in pro-inflammatory macrophage activation and identified its prominent and specific role in the activation of NF-kB. A positive regulation between NOTCH and NF-kB signaling pathway has been described previously in macrophages isolated from patients with atherosclerosis. In those patients, and in contrast with our results,[5] \n",
      "query: What is the therapeutic target for CADASIL? \n",
      "summarize given evidences and query:Syk is a therapeutic target for CADASIL. In CADASIL, proinflammatory signaling is activated[1] through the increase of TGFb1 signaling[2]. The apoptosis of vascular smooth muscle cell (VSMC) and increased TGFb1 signaling cause fibrosis and vascular abnormalities in vascular epithelial cells[3]. Syk increases fibrosis through activation of TGFb1 signaling[4]. \n",
      "\n",
      "evidence 0: There is currently no consensus on whether CADASIL mutations generate hyperactive or hypoactive Notch3 proteins with regard to downstream signaling or whether CADASIL mutations are neutral in terms of Notch signaling. Whereas the R169C mutation appeared to lead to hyperactive Notch signaling (see above), the R1031C or C455R mutations were instead shown to be hypoactive,36[1] \n",
      "evidence 1: Our work confirms and highlights the relevance of NOTCH3 expression and signaling in pro-inflammatory macrophage activation and identified its prominent and specific role in the activation of NF-kB. A positive regulation between NOTCH and NF-kB signaling pathway has been described previously in macrophages isolated from patients with atherosclerosis. In those patients, and in contrast with our results,[5] \n",
      "evidence 2: Niclosamide and derivatives - potent inhibitors of TMEM16A/F and Ca2+ signaling. NFA is a nonsteroidal anti-inflammatory compound that inhibits goblet cell degranulation and suppresses asthma phenotype (4, 27). ...This result suggests an antiinflammatory effect of niclosamide, which corresponds well to inhibition of allergic lung inflammation by the TMEM16A inhibitor benzbromarone (3, 31).[6] \n",
      "evidence 3: The key findings of this study are that (a) Cl- fluxes mediated by the Ca2+gated channel TMEM16A are a crucial determinant of pericyte tone; (b) TMEM16A is activated during ischemia and evokes a long-lasting pericytemediated capillary constriction that reduces CBF and favors neutrophil and platelet stalling; (c) genetic analysis suggests that increased TMEM16A expression is associated with poor recovery after ischemic stroke (and the genetic proxy[7] \n",
      "query: What is the therapeutic target for CADASIL? \n",
      "summarize given evidences and query:\n",
      "\n",
      "\n",
      "< GENERATED >\n",
      "\n",
      "['the prevailing view is that the inflammatory response is essential for the development of lung fibrosis. <n> this view has recently been challenged by the discovery of a new signaling pathway that is essential for the development of lung fibrosis. <n> this pathway is activated by tnf-, a cytokine that has been implicated in the pathogenesis of several diseases, including lung fibrosis. <n> the key molecule in this pathway, tnf- binding protein 1 ( tnf - binding protein 1, tbp1 ), is a member of the nuclear factor kappa b ( nf-b ) family of transcription factors. <n> tbp1 belongs to the large family of nf-b - related proteins ( nf-b / nf-b - like, nf-b / nf-b2, nf-b / nf-b3, nf-b / nf-b4, nf-b / nf-b5, nf-b / nf-b6, nf-b / nf-b7, nf-b / nf-b8, nf-b / nf-b9, nf-b / nf-b10, nf-b / nf-b11, and nf-b / nf-b12. <n> it is activated by tnf- ( tnf- ) and its downstream effectors ( tbp1, tbp1, tbp2, tbp3, and tbp3. tbp1., tbp2, and. tbp1 and tbp2 was specifically activated by tbp.. tbp, whereas tbp and, tbp and tbp and tbp and, the major effector tbp, the major effector of tbp and its downstream molecules ( tbp and its downstream molecules were all the major molecules were all.. tbp. : tbp. tbp.. tbp.... tbp. tbp.... tbp... tbp. <n> the recent studies will provide insight into the relevance for the discovery of the relevance of the relevance of the relevance of the significance of the relevance of the relevance of the relevance of the relevance of the relevant pathways and the relevance of the relevance of the relevant 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 800-273-3217 <n> <n>. <n> <n> <n> <n> <n> <n> <n> <n>. <n>. <n> <n>. <n>. <n> <n>. <n> <n>...']\n",
      "\n",
      "###############################################################################################################################################################\n",
      "\n",
      "< PROMPT >\n",
      "\n",
      "evidence 0: There is currently no consensus on whether CADASIL mutations generate hyperactive or hypoactive Notch3 proteins with regard to downstream signaling or whether CADASIL mutations are neutral in terms of Notch signaling. Whereas the R169C mutation appeared to lead to hyperactive Notch signaling (see above), the R1031C or C455R mutations were instead shown to be hypoactive,36[1] \n",
      "evidence 1: Our work confirms and highlights the relevance of NOTCH3 expression and signaling in pro-inflammatory macrophage activation and identified its prominent and specific role in the activation of NF-kB. A positive regulation between NOTCH and NF-kB signaling pathway has been described previously in macrophages isolated from patients with atherosclerosis. In those patients, and in contrast with our results,[5] \n",
      "evidence 2: Niclosamide and derivatives - potent inhibitors of TMEM16A/F and Ca2+ signaling. NFA is a nonsteroidal anti-inflammatory compound that inhibits goblet cell degranulation and suppresses asthma phenotype (4, 27). ...This result suggests an antiinflammatory effect of niclosamide, which corresponds well to inhibition of allergic lung inflammation by the TMEM16A inhibitor benzbromarone (3, 31).[6] \n",
      "evidence 3: The key findings of this study are that (a) Cl- fluxes mediated by the Ca2+gated channel TMEM16A are a crucial determinant of pericyte tone; (b) TMEM16A is activated during ischemia and evokes a long-lasting pericytemediated capillary constriction that reduces CBF and favors neutrophil and platelet stalling; (c) genetic analysis suggests that increased TMEM16A expression is associated with poor recovery after ischemic stroke (and the genetic proxy[7] \n",
      "query: What is the therapeutic target for CADASIL? \n",
      "summarize given evidences and query:TMEM16A is a therapeutic target for CADASIL. Ischemia in CADASIL activates TMEM16A, Ca2+ gated Cl- channel, which regulates pericyte tone and induces capillary constriction[1]. Potent inhibitors of TMEM16A, niclosamide has antiinflammtory effect[2]. Niclosamide can suppress enhance inflammation in CADASIL[3]. \n",
      "\n",
      "evidence 0: There is currently no consensus on whether CADASIL mutations generate hyperactive or hypoactive Notch3 proteins with regard to downstream signaling or whether CADASIL mutations are neutral in terms of Notch signaling. Whereas the R169C mutation appeared to lead to hyperactive Notch signaling (see above), the R1031C or C455R mutations were instead shown to be hypoactive,36[1] \n",
      "evidence 1: We believe that increased TGFb3 reflects an inflammatory condition and even an involvement of TGFb in fibrosis in CADASIL. Support for our hypothesis is the outcome of several studies that showed NOTCH3 and TGFb1 signalling play a key role in the pathogenesis and progression of chronic cardiovascular disease.[2] \n",
      "evidence 2: Over time, VSMCs apoptosis leads to fibrosis and thickening of the arterial wall, progressive lumen stenosis and vascular insufficiency that makes the already poorly perfused terminal regions particularly susceptible to infarcts. SMCs degeneration is followed by the emergence of large,...[3] \n",
      "evidence 3: Previously published studies have shown that TGF-b signaling is closely associated with the activity of SYK, and the kinase activity of SYK is essential for the activation of some signaling receptor downstream effector molecules[25]. ...bidirectional[33]. In the present study, the activation of SYK was shown to increase the progression of peritoneal fibrosis through activation of the TGF-b1/Smad3 signaling pathway, and inhibition of TGF-b1 also resulted in down-regulation of SYK.[4] \n",
      "evidence 4: Our work confirms and highlights the relevance of NOTCH3 expression and signaling in pro-inflammatory macrophage activation and identified its prominent and specific role in the activation of NF-kB. A positive regulation between NOTCH and NF-kB signaling pathway has been described previously in macrophages isolated from patients with atherosclerosis. In those patients, and in contrast with our results,[5] \n",
      "query: What is the therapeutic target for CADASIL? \n",
      "summarize given evidences and query:\n",
      "\n",
      "\n",
      "< GENERATED >\n",
      "\n",
      "['recent advances in the understanding of the molecular mechanisms of cardiovascular disease ( cvd ) have led to a better understanding of the pathomechanisms underlying the disease. <n> for example, it has become clear that inflammation plays an important role in the development and progression of cvd. <n> in addition, it has become clear that the vasoconstrictor nicotinamide adenine dinucleotide phosphate ( nadph)-binding protein ( nadp+ ) and its receptor, nadp+/nadh dehydrogenase 1 ( nad1/nadh1 ), are critical for the development and progression of cvd. in this review, we summarize the current knowledge on the role of inflammation and nadp+ in the development and progression of cvd.']\n",
      "\n",
      "###############################################################################################################################################################\n",
      "\n",
      "< PROMPT >\n",
      "\n",
      "evidence 0: Role of NOTCH3 Mutations in the Cerebral Small Vessel Disease Cerebral Autosomal Dominant Arteriopathy ... (Stroke 2018). There is currently no consensus on whether CADASIL mutations generate hyperactive or hypoactive Notch3 proteins with ...[1] \n",
      "evidence 1: Differences in proliferation rate between CADASIL and control vascular smooth muscle cells are ... (J Cell Mol Med 2018). We believe that increased TGFb3 reflects an inflammatory condition and even an involvement of TGFb in fibrosis in CADASIL. ... showed NOTCH3 and TGFb1 signalling play a key role in the pathogenesis and progression of chronic...[2] \n",
      "evidence 2: The Role of Vascular Smooth Muscle Cells in Arterial Remodeling: Focus on Calcification ... (Int J Mol Sci 2019). Over time, VSMCs apoptosis leads to fibrosis and thickening of the arterial wall, progressive lumen stenosis and vascular insufficiency that makes the already poorly perfused ...[3] \n",
      "evidence 3: Spleen Tyrosine Kinase (SYK) in the Progression of Peritoneal Fibrosis Through Activation of the ... (Med Sci Monit 2019). Previously published studies have shown that TGF-b signaling is closely associated with the activity of SYK, and the kinase ...[4] \n",
      "evidence 4: NOTCH3 signaling is essential for NF-kB activation in TLRactivated macrophages (Sci Rep 2020). Our work confirms and highlights the relevance of NOTCH3 expression and signaling in pro-inflammatory macrophage ...[5] \n",
      "query: What is the therapeutic target for CADASIL? \n",
      "summarize given evidences and query:Syk is a therapeutic target for CADASIL. In CADASIL, proinflammatory signaling is activated[1] through the increase of TGFb1 signaling[2] . The apoptosis of vascular smooth muscle cell (VSMC) and increased TGFb1 signaling cause fibrosis and vascular abnormalities in vascular epithelial cells[3] . Syk increases fibrosis through activation of TGFb1 signaling[4]. \n",
      "\n",
      "evidence 0: Role of NOTCH3 Mutations in the Cerebral Small Vessel Disease Cerebral Autosomal Dominant Arteriopathy ... (Stroke 2018). There is currently no consensus on whether CADASIL mutations generate hyperactive or hypoactive Notch3 proteins with ...[1] \n",
      "evidence 1: NOTCH3 signaling is essential for NF-kB activation in TLRactivated macrophages (Sci Rep 2020). Our work confirms and highlights the relevance of NOTCH3 expression and signaling in pro-inflammatory macrophage ...[5] \n",
      "evidence 2: Niclosamide repurposed for the treatment of inflammatory airway disease (JCI Insight 2019). Niclosamide and derivatives - potent inhibitors of TMEM16A/F and Ca2+ signaling. NFA is a nonsteroidal antiinflammatory compound that inhibits goblet ...[6] \n",
      "evidence 3: The Ca2+-gated channel TMEM16A amplifies capillary pericyte contraction and reduces ... (J Clin Invest. 2022). The key findings of this study are that (a) Cl- fluxes mediated by the Ca2+-gated channel TMEM16A are a crucial determinant of pericyte tone[7] \n",
      "query: What is the therapeutic target for CADASIL? \n",
      "summarize given evidences and query:\n",
      "\n",
      "\n",
      "< GENERATED >\n",
      "\n",
      "['abstractevidence shows that vascular smooth muscle cells ( vsmcs ) activate mitogen - activated protein kinase ( mapk ) and mapk - dependent kinase 1 ( mapk1 ) in response to vascular injury. <n> mapk1 phosphorylates and activates mapk2, which in turn phosphorylates and activates mapk3. <n> mapk1 phosphorylates and activates mapk3, which in turn phosphorylates and activates mapk4. <n> mapk1 phosphorylates and activates mapk5, which in turn phosphorylates and activates mapk6. <n> mapk6 phosphorylates and activates mapk7, which in turn phosphorylates and activates mapk8. <n> mapk7 phosphorylates and activates mapk9, which in turn phosphorylates and activates mapk10. <n> mapk10 phosphorylates and activates mapk11, which in turn phosphorylates and activates mapk12. <n> mapk1 phosphorylates and activates mapk13, which in turn phosphorylates and activates mapk14. <n> mapk7 phosphorylates and activates mapk16, which in turn phosphorylates and activates mapk17. <n> mapk7 phosphorylates and activates mapk18. <n> mapk1 phosphorylates and activates mapk9, mapk10. <n> mapk and mapk10.']\n",
      "\n",
      "###############################################################################################################################################################\n",
      "\n",
      "< PROMPT >\n",
      "\n",
      "evidence 0: Role of NOTCH3 Mutations in the Cerebral Small Vessel Disease Cerebral Autosomal Dominant Arteriopathy ... (Stroke 2018). There is currently no consensus on whether CADASIL mutations generate hyperactive or hypoactive Notch3 proteins with ...[1] \n",
      "evidence 1: NOTCH3 signaling is essential for NF-kB activation in TLRactivated macrophages (Sci Rep 2020). Our work confirms and highlights the relevance of NOTCH3 expression and signaling in pro-inflammatory macrophage ...[5] \n",
      "evidence 2: Niclosamide repurposed for the treatment of inflammatory airway disease (JCI Insight 2019). Niclosamide and derivatives - potent inhibitors of TMEM16A/F and Ca2+ signaling. NFA is a nonsteroidal antiinflammatory compound that inhibits goblet ...[6] \n",
      "evidence 3: The Ca2+-gated channel TMEM16A amplifies capillary pericyte contraction and reduces ... (J Clin Invest. 2022). The key findings of this study are that (a) Cl- fluxes mediated by the Ca2+-gated channel TMEM16A are a crucial determinant of pericyte tone[7] \n",
      "query: What is the therapeutic target for CADASIL? \n",
      "summarize given evidences and query:TMEM16A is a therapeutic target for CADASIL. Ischemia in CADASIL activates TMEM16A, Ca2+ gated Cl- channel, which regulates pericyte tone and induces capillary constriction[1]. Potent inhibitors of TMEM16A, niclosamide has antiinflammtory effect[2]. Niclosamide can suppress enhance inflammation in CADASIL[3]. \n",
      "\n",
      "evidence 0: Role of NOTCH3 Mutations in the Cerebral Small Vessel Disease Cerebral Autosomal Dominant Arteriopathy ... (Stroke 2018). There is currently no consensus on whether CADASIL mutations generate hyperactive or hypoactive Notch3 proteins with ...[1] \n",
      "evidence 1: Differences in proliferation rate between CADASIL and control vascular smooth muscle cells are ... (J Cell Mol Med 2018). We believe that increased TGFb3 reflects an inflammatory condition and even an involvement of TGFb in fibrosis in CADASIL. ... showed NOTCH3 and TGFb1 signalling play a key role in the pathogenesis and progression of chronic...[2] \n",
      "evidence 2: The Role of Vascular Smooth Muscle Cells in Arterial Remodeling: Focus on Calcification ... (Int J Mol Sci 2019). Over time, VSMCs apoptosis leads to fibrosis and thickening of the arterial wall, progressive lumen stenosis and vascular insufficiency that makes the already poorly perfused ...[3] \n",
      "evidence 3: Spleen Tyrosine Kinase (SYK) in the Progression of Peritoneal Fibrosis Through Activation of the ... (Med Sci Monit 2019). Previously published studies have shown that TGF-b signaling is closely associated with the activity of SYK, and the kinase ...[4] \n",
      "evidence 4: NOTCH3 signaling is essential for NF-kB activation in TLRactivated macrophages (Sci Rep 2020). Our work confirms and highlights the relevance of NOTCH3 expression and signaling in pro-inflammatory macrophage ...[5] \n",
      "query: What is the therapeutic target for CADASIL? \n",
      "summarize given evidences and query:\n",
      "\n",
      "\n",
      "< GENERATED >\n",
      "\n",
      "['interleukin-6 ( il-6 ) is a member of the tumor necrosis factor ( tnf ) superfamily, which has been implicated in the pathogenesis of a number of inflammatory - based diseases. <n> recent studies suggest that il-6 may play a role in the pathogenesis of rheumatoid arthritis ( ra ), an inflammatory arthritis. <n> we recently reported that il-6 is upregulated in peripheral blood mononuclear cells ( pbmcs ) of patients with ra. <n> pbmcs from ra patients expressed higher levels of il-6 and lower levels of its downstream target, nuclear factor-b ( nf-b ), than pbmcs from healthy donors. <n> pbmcs from ra patients expressed higher levels of il-6 and lower levels of its downstream target, nuclear factor-b ( nf-b ), than pbmcs from healthy donors. <n> in addition, pbmcs from ra patients expressed higher levels of il-6 and lower levels of its downstream target, nuclear factor-b ( nf-b ), than pbmcs from healthy donors. <n> thus, our findings suggest that il-6 may play a role in the pathogenesis of ra by regulating nf-b activity in pbmcs.']\n",
      "\n",
      "###############################################################################################################################################################\n",
      "\n",
      "< PROMPT >\n",
      "\n",
      "evidence 0: Here we report the characterization of the human Notch3 gene which we mapped to the CADASIL critical region. We have identified mutations in CADASIL patients that cause serious disruption of this gene, indicating that Notch3 could be the defective protein in CADASIL patients.All these missense mutations may result in severe disruption of the Notch3 protein, as suggested by the highly conserved nature of the aminoacid residues involved, particularly the cysteines that are key features of EGF likedomains24. These results indicate that these nucleotide substitutions are pathogenic mutations rather than rare polymorphisms.[1] \n",
      "evidence 1: Linkage studies in other families enabled further refinement of this genetic interval16,17 and identification of the mutated gene as NOTCH3 (Notch homolog 3).18[2] \n",
      "evidence 2: CADASIL, a hereditary vascular dementia, suggesting a role for Notch3 in vessel homeostasis (Joutel et al. 1996). CADASIL is a late-onset disorder, and neurological symptoms arise from a slowly developing systemic vasculopathy, characterized ultimately by degeneration of VSMC. ...maturation of VSMC, and ends around P28 when the artery acquires its final shape. We identify Notch3 to be the first key player of this process, by regulating cell-autonomously the arterial differentiation and maturation of VSMC.[3] \n",
      "query: What is the cause of the CADASIL? \n",
      "summarize given evidences and query:CADASIL is a rare hereditary cerebrovascular disease caused by a NOTCH3 mutation[1][2]. NOTCH3 is particularly important for the maturation of vascular smooth muscle cells (VSMCs). A decreased VSMC is a pathological hallmark for CADASIL[3]. \n",
      "\n",
      "evidence 0: CADASIL) is sometimes misdiagnosed as multiple sclerosis (MS). MS and CADASIL are not known to co-occur and brain magnetic resonance imagining (MRI) findings can help with differential diagnosis. Despite the availability of this information, a case report is presented of a 61-year-old woman who was misdiagnosed with MS at age 50, tested positive for CADASIL at age 56, described incorrectly as having both conditions simultaneously, and continued on MS disease-modifying medications, resulting in financial and physical hardship.[1] \n",
      "evidence 1: Despite the availability of this information, a case report is presented of a 61-year-old woman who was misdiagnosed with MS at age 50, tested positive for CADASIL at age 56, described incorrectly as having both conditions simultaneously, and continued on MS disease-modifying medications, resulting in financial and physical hardship. Neuropsychological consultation helped initiate removal of the MS diagnosis and treatment. Better understanding is needed among clinicians that MS and CADASIL are not known to co-exist, that no association has been found between MS and the NOTCH3 mutations that cause CADASIL, and that neuroimaging and clinical features can help distinguish between the two conditions in addition to genetic testing.[2] \n",
      "evidence 2: Antithrombotic drugs were used in three patients, in one for an unrelated coexisting prothrombotic condition. CADASIL does not seem to be associated with an unfavorable outcome of pregnancy either for women and fetuses. Patients and treating physicians should be reassured that pregnancy can be safely initiated in CADASIL, as there is no evidence to support a specific preventive antithrombotic treatment during pregnancy in CADASIL.[3] \n",
      "query: can nilvadipine help alleviate cadasil symptoms? \n",
      "summarize given evidences and query:\n",
      "\n",
      "\n",
      "< GENERATED >\n",
      "\n",
      "['background : there are many causes to be misdiagnosed, such as diseases of the nervous system, vascular diseases, such as parkinson s disease ( pd ), multiple sclerosis ( ms ), alzheimer s disease ( ad ), and huntington s disease ( hd ). <n> it is important to distinguish the causes of these diseases, so that appropriate treatment can be initiated.methods: in this article, we summarize the evidence for causes of the following diseases : ( 1 ) pd, ( 2 ) hd, ( 3 ) ad, ( 4 ) amyotrophic lateral sclerosis ( als ), ( 5 ) huntington s disease ( hd ), ( 6 ) alzheimer s disease ( ad ), ( 7 ) amyotrophic lateral sclerosis ( als ), ( 8) parkinson s disease ( pd ), ( 9 ) ms, ( 10 ) ad, ( 11 ) hd, ( 12 ) ad, ( 13 ) hd, ( 14 ) alzheimer s disease ( ad ), ( 15 ) ad, ( 16 ) hd, ( 17 ) ad, ( 18 ) hd, ( 19 ) ms, ( 20 ) pd.results : ( 1 ) pd, ( 2 ) hd, ( 3 ) ad, ( 4 ) als, ( 5 ) pd, ( 21 ) ad, ( 22 ) hd. conclusions : ( 19 : ( 20 : ( 20 ) it is important to distinguish the causes of pd. ( 1 ). ( 1. ( 1 ). ( 1 ) it is the cause of the cause of the cause of the cause of the cause of the cause of the disease.. the cause of the disease. it is the cause of the disease. it is the cause of the cause of the disease. the disease. it is the cause of the disease. how can one. how can one. the diagnosis. it also. how can one. it also. it also. it also. it also. it also. it also. also. it also. also. it also. also. also. it also. also. also. it also. also. it also. it also. also. also. also. it. it also. it. also. also. also. it. it. it also. it. it also. also. also. also <n> it. also <n> it. also <n> it. also. also. it. it also. also. also <n> it. also <n> also <n> it, it, and also. it also.<n> additionally.<n> additionally <n> additionally. it. it also.<n> additionally.<n> additionally. it. it, and also. it, and it, and also. it. it. it also. it. it also. it also. it. it also. it also.<n> it also. it. it also. it also. it also. it also. it. it also. it also. it.<n> also. it also. it.it.<n> also.<n> it. it also. it also. it.<n> it.<n> also.<n> it.<n> it.<n> it.<n> it.<n> it.<n> it.<n> it.<n> also..<n> also..<n> it.<n> it.<n> it.<n> it.<n> it.<n> it.<n> also.<n> it.<n> it.<n> it.<n> also.<n> it.<n> it.<n> it.<n> also.<n> it.<n> it.<n> also.<n> also.<n> it. <n> also.<n> it. <n> also. <n> also.<n> also.it...<n> it.it.<n> also.<n> also.it. <n> it.<n> also.it.it.it.it..']\n",
      "\n",
      "###############################################################################################################################################################\n",
      "\n",
      "< PROMPT >\n",
      "\n",
      "evidence 0: There is currently no consensus on whether CADASIL mutations generate hyperactive or hypoactive Notch3 proteins with regard to downstream signaling or whether CADASIL mutations are neutral in terms of Notch signaling. Whereas the R169C mutation appeared to lead to hyperactive Notch signaling (see above), the R1031C or C455R mutations were instead shown to be hypoactive,36[1] \n",
      "evidence 1: We believe that increased TGFb3 reflects an inflammatory condition and even an involvement of TGFb in fibrosis in CADASIL. Support for our hypothesis is the outcome of several studies that showed NOTCH3 and TGFb1 signalling play a key role in the pathogenesis and progression of chronic cardiovascular disease.[2] \n",
      "evidence 2: Over time, VSMCs apoptosis leads to fibrosis and thickening of the arterial wall, progressive lumen stenosis and vascular insufficiency that makes the already poorly perfused terminal regions particularly susceptible to infarcts. SMCs degeneration is followed by the emergence of large,...[3] \n",
      "evidence 3: Previously published studies have shown that TGF-b signaling is closely associated with the activity of SYK, and the kinase activity of SYK is essential for the activation of some signaling receptor downstream effector molecules[25]. ...bidirectional[33]. In the present study, the activation of SYK was shown to increase the progression of peritoneal fibrosis through activation of the TGF-b1/Smad3 signaling pathway, and inhibition of TGF-b1 also resulted in down-regulation of SYK.[4] \n",
      "evidence 4: Our work confirms and highlights the relevance of NOTCH3 expression and signaling in pro-inflammatory macrophage activation and identified its prominent and specific role in the activation of NF-kB. A positive regulation between NOTCH and NF-kB signaling pathway has been described previously in macrophages isolated from patients with atherosclerosis. In those patients, and in contrast with our results,[5] \n",
      "query: What is the therapeutic target for CADASIL? \n",
      "summarize given evidences and query:Syk is a therapeutic target for CADASIL. In CADASIL, proinflammatory signaling is activated[1] through the increase of TGFb1 signaling[2]. The apoptosis of vascular smooth muscle cell (VSMC) and increased TGFb1 signaling cause fibrosis and vascular abnormalities in vascular epithelial cells[3]. Syk increases fibrosis through activation of TGFb1 signaling[4]. \n",
      "\n",
      "evidence 0: CADASIL) is sometimes misdiagnosed as multiple sclerosis (MS). MS and CADASIL are not known to co-occur and brain magnetic resonance imagining (MRI) findings can help with differential diagnosis. Despite the availability of this information, a case report is presented of a 61-year-old woman who was misdiagnosed with MS at age 50, tested positive for CADASIL at age 56, described incorrectly as having both conditions simultaneously, and continued on MS disease-modifying medications, resulting in financial and physical hardship.[1] \n",
      "evidence 1: Despite the availability of this information, a case report is presented of a 61-year-old woman who was misdiagnosed with MS at age 50, tested positive for CADASIL at age 56, described incorrectly as having both conditions simultaneously, and continued on MS disease-modifying medications, resulting in financial and physical hardship. Neuropsychological consultation helped initiate removal of the MS diagnosis and treatment. Better understanding is needed among clinicians that MS and CADASIL are not known to co-exist, that no association has been found between MS and the NOTCH3 mutations that cause CADASIL, and that neuroimaging and clinical features can help distinguish between the two conditions in addition to genetic testing.[2] \n",
      "evidence 2: Antithrombotic drugs were used in three patients, in one for an unrelated coexisting prothrombotic condition. CADASIL does not seem to be associated with an unfavorable outcome of pregnancy either for women and fetuses. Patients and treating physicians should be reassured that pregnancy can be safely initiated in CADASIL, as there is no evidence to support a specific preventive antithrombotic treatment during pregnancy in CADASIL.[3] \n",
      "query: can nilvadipine help alleviate cadasil symptoms? \n",
      "summarize given evidences and query:\n",
      "\n",
      "\n",
      "< GENERATED >\n",
      "\n",
      "['evidence 0: currently, there is no consensus on whether mutations generate or hypoactive3 signaling proteins. <n> this leads to the following query : what is the target of hypoactive3 signaling? <n> we summarize evidence 0: currently, there is no consensus on whether mutations are hyperactive or hypoactive3 signaling proteins. <n> this leads to the following query : what is the target of hypoactive3 signaling? <n> we summarize evidence 0: currently, there is no consensus on whether mutations are hyperactive or hypoactive3 signaling proteins. <n> this leads to the following query : what is the target of hypoactive3 signaling? <n> we summarize evidence 0: currently, there is no consensus on whether mutations are hyperactive or hypoactive3 signaling proteins. <n> this leads to the following query : what is the target of hypoactive3 signaling? <n> we summarize evidence 0: currently, there is no consensus on whether mutations are hyperactive or hypoactive3 signaling proteins. <n> this leads to the following query : what is the target of hypoactive3 signaling? <n> we summarize evidence 0: currently, there is no consensus on whether mutations are hyperactive or hypoactive3 signaling proteins. <n> this leads to the following query : what is the target of hypoactive3 signaling? <n> we summarize evidence 0: currently, there is no consensus on whether mutations are hyperactive or neutral3 proteins. <n> evidence 0 : there is currently, there is no consensus on whether mutations on the nature of the nature of the molecular biology of the molecular biology of the molecular biology of the molecular biology of the molecular biology of the molecular biology of the molecular biology of the molecular biology of the molecular biology of molecular biology of molecular biology of molecular biology of molecular biology of molecular biology of molecular biology of the molecular biology of molecular biology of molecular biology of molecular biology of molecular biology of molecular biology of the molecular biology of the molecular biology ofonnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnieronnier <n> <n> <n> <n> <n> <n> <n> <n> <n>']\n",
      "\n",
      "###############################################################################################################################################################\n",
      "\n",
      "< PROMPT >\n",
      "\n",
      "evidence 0: There is currently no consensus on whether CADASIL mutations generate hyperactive or hypoactive Notch3 proteins with regard to downstream signaling or whether CADASIL mutations are neutral in terms of Notch signaling. Whereas the R169C mutation appeared to lead to hyperactive Notch signaling (see above), the R1031C or C455R mutations were instead shown to be hypoactive,36[1] \n",
      "evidence 1: Our work confirms and highlights the relevance of NOTCH3 expression and signaling in pro-inflammatory macrophage activation and identified its prominent and specific role in the activation of NF-kB. A positive regulation between NOTCH and NF-kB signaling pathway has been described previously in macrophages isolated from patients with atherosclerosis. In those patients, and in contrast with our results,[5] \n",
      "evidence 2: Niclosamide and derivatives - potent inhibitors of TMEM16A/F and Ca2+ signaling. NFA is a nonsteroidal anti-inflammatory compound that inhibits goblet cell degranulation and suppresses asthma phenotype (4, 27). ...This result suggests an antiinflammatory effect of niclosamide, which corresponds well to inhibition of allergic lung inflammation by the TMEM16A inhibitor benzbromarone (3, 31).[6] \n",
      "evidence 3: The key findings of this study are that (a) Cl- fluxes mediated by the Ca2+gated channel TMEM16A are a crucial determinant of pericyte tone; (b) TMEM16A is activated during ischemia and evokes a long-lasting pericytemediated capillary constriction that reduces CBF and favors neutrophil and platelet stalling; (c) genetic analysis suggests that increased TMEM16A expression is associated with poor recovery after ischemic stroke (and the genetic proxy[7] \n",
      "query: What is the therapeutic target for CADASIL? \n",
      "summarize given evidences and query:TMEM16A is a therapeutic target for CADASIL. Ischemia in CADASIL activates TMEM16A, Ca2+ gated Cl- channel, which regulates pericyte tone and induces capillary constriction[1]. Potent inhibitors of TMEM16A, niclosamide has antiinflammtory effect[2]. Niclosamide can suppress enhance inflammation in CADASIL[3]. \n",
      "\n",
      "evidence 0: CADASIL) is sometimes misdiagnosed as multiple sclerosis (MS). MS and CADASIL are not known to co-occur and brain magnetic resonance imagining (MRI) findings can help with differential diagnosis. Despite the availability of this information, a case report is presented of a 61-year-old woman who was misdiagnosed with MS at age 50, tested positive for CADASIL at age 56, described incorrectly as having both conditions simultaneously, and continued on MS disease-modifying medications, resulting in financial and physical hardship.[1] \n",
      "evidence 1: Despite the availability of this information, a case report is presented of a 61-year-old woman who was misdiagnosed with MS at age 50, tested positive for CADASIL at age 56, described incorrectly as having both conditions simultaneously, and continued on MS disease-modifying medications, resulting in financial and physical hardship. Neuropsychological consultation helped initiate removal of the MS diagnosis and treatment. Better understanding is needed among clinicians that MS and CADASIL are not known to co-exist, that no association has been found between MS and the NOTCH3 mutations that cause CADASIL, and that neuroimaging and clinical features can help distinguish between the two conditions in addition to genetic testing.[2] \n",
      "evidence 2: Antithrombotic drugs were used in three patients, in one for an unrelated coexisting prothrombotic condition. CADASIL does not seem to be associated with an unfavorable outcome of pregnancy either for women and fetuses. Patients and treating physicians should be reassured that pregnancy can be safely initiated in CADASIL, as there is no evidence to support a specific preventive antithrombotic treatment during pregnancy in CADASIL.[3] \n",
      "query: can nilvadipine help alleviate cadasil symptoms? \n",
      "summarize given evidences and query:\n",
      "\n",
      "\n",
      "< GENERATED >\n",
      "\n",
      "['in a recent article in frontiers in pharmacology, dr. <n> sam wang and colleagues summarize the results of an international workshop entitled the pharmacology of cardiovascular disease ( cvd ) : progress and perspectives. <n> this workshop was held in march 2014 in washington, dc, usa, in conjunction with the annual meeting of the european society of cardiology ( esc ). <n> the aim of the workshop was to assess the progress and perspectives in the field of cvd and to identify future research directions. <n> the meeting was held in april 2014 in washington, dc, usa, in conjunction with the annual meeting of the european society of cardiology ( esc ). <n> the aim of the workshop was to assess the progress and perspectives in the field of cvd and to identify future research directions. <n> the meeting was held in april 2014 in washington, dc, usa, in conjunction with the annual meeting of the european society of cardiology ( esc ).']\n",
      "\n",
      "###############################################################################################################################################################\n",
      "\n",
      "< PROMPT >\n",
      "\n",
      "evidence 0: Here we report the characterization of the human Notch3 gene which we mapped to the CADASIL critical region. We have identified mutations in CADASIL patients that cause serious disruption of this gene, indicating that Notch3 could be the defective protein in CADASIL patients.All these missense mutations may result in severe disruption of the Notch3 protein, as suggested by the highly conserved nature of the aminoacid residues involved, particularly the cysteines that are key features of EGF likedomains24. These results indicate that these nucleotide substitutions are pathogenic mutations rather than rare polymorphisms.[1] \n",
      "evidence 1: Linkage studies in other families enabled further refinement of this genetic interval16,17 and identification of the mutated gene as NOTCH3 (Notch homolog 3).18[2] \n",
      "evidence 2: CADASIL, a hereditary vascular dementia, suggesting a role for Notch3 in vessel homeostasis (Joutel et al. 1996). CADASIL is a late-onset disorder, and neurological symptoms arise from a slowly developing systemic vasculopathy, characterized ultimately by degeneration of VSMC. ...maturation of VSMC, and ends around P28 when the artery acquires its final shape. We identify Notch3 to be the first key player of this process, by regulating cell-autonomously the arterial differentiation and maturation of VSMC.[3] \n",
      "query: What is the cause of the CADASIL? \n",
      "summarize given evidences and query:CADASIL is a rare hereditary cerebrovascular disease caused by a NOTCH3 mutation[1][2]. NOTCH3 is particularly important for the maturation of vascular smooth muscle cells (VSMCs). A decreased VSMC is a pathological hallmark for CADASIL[3]. \n",
      "\n",
      "evidence 0: Using both wild type mice and transgenic mice carrying the human mutant Notch3 gene (CADASIL mice), we have recently characterized the pathological features of CADASIL and determined the therapeutic efficacy of two hematopoietic growth factors, stem cell factor (SCF) and granulocyte colony-stimulating factor (G-CSF) in CADASIL. Our findings have revealed novel pathological changes in the endothelium of cerebral capillaries and in the neural stem cells (NSCs). We have also observed the impairment of cognitive function in CADASIL mice.[1] \n",
      "evidence 1: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common condition of hereditary stroke and vascular dementia. CADASIL is caused by Notch3 mutation, leading to progressive degeneration of vascular smooth muscle cells (VSMCs) of the small arteries in the brain. However, the pathogenesis of CADASIL remains largely unknown, and treatment that can stop or delay the progression of CADASIL is not yet available.[2] \n",
      "evidence 2: Today, CADASIL is known to every neurologist, but the disease has not yet revealed all its secrets. A lot of effort is still needed to understand the intimate mechanisms of the disease and the most efficient targets or approaches for the development of efficient therapeutics. The history of CADASIL will be further enriched by multiple ongoing research projects worldwide, at clinical and preclinical level, and will continue to enlighten research in the field of cerebral small vessel disorders.[3] \n",
      "query: what are the potential therapeutic targets for cadasil? \n",
      "summarize given evidences and query:\n",
      "\n",
      "\n",
      "< GENERATED >\n",
      "\n",
      "['the gene that encodes neuregulin 3 ( neur3 ), a member of the neuregulin family of proteins, is expressed in the central nervous system ( cns ). <n> loss of neur3 function has been associated with several neurological disorders, including alzheimer s disease ( ad ), parkinson s disease ( pd ), huntington s disease ( hd ), amyotrophic lateral sclerosis ( als ), alzheimer s disease ( ad ), amyotrophic lateral sclerosis ( als ), and amyotrophic lateral sclerosis ( als ). <n> the loss of neur3 function has also been associated with alzheimer s disease ( ad ), pd, hd, amyotrophic lateral sclerosis ( als ), and parkinson s disease ( pd ). <n> the loss of neur3 function has been also associated with alzheimer s disease ( ad ), pd, hd, amyotrophic lateral sclerosis ( als ), and parkinson s disease ( pd ). <n> the loss of neur3 function has been associated with alzheimer s disease ( ad ), pd, hd, amyotrophic lateral sclerosis ( als ), and parkinson s disease ( pd ). <n> the loss of neur3 function has been associated with alzheimer s disease ( ad ), pd, hd, and amyotrophic lateral sclerosis ( als )... <n> the loss of neur3 function of the neur3 function of the neur3 is also associated with ad., the loss of neuronal function of the neur3 of the neur3 of the neur3 of the neur3 of the neur neurons. neur neurons of the cns... <n> the neur neurons of the neur neurons of the cns.... the loss of the. the neur neurons of the neurons of the neurons of the neurons of the.... <n> the neuron ( neurotrophtrophtrophtrophtrophtrophtrophtrophtrophtrophtrophtrophtrophtrophtrophtrophtrophtrophtrophtrophtrophtrophtrophtrophtrophtrophtrophtrophtrophtrophtrophtrophtrophtroph propagate propagate propagate propagate propagate propagate propagate propagate propagate propagate propagate polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl ( polyvinyl... <n> the. <n> the <n> the <n> the <n> <n> <n> the <n> the <n> the <n> <n> <n> <n> <n> <n>  polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl polyvinyl <n> polyvinyl polyvinyl <n> polyvinyl <n> polyvinyl <n> polyvinyl <n> polyvinyl <n> polyvinyl <n> polyvinyl <n> polyvinyl <n> polyvinyl <n> polyvinyl.<n> the polyvinyl <n> polyvinyl. <n> the polyvinyl. <n> the polyvinyl. <n> the polyvinyl <n> polyvinyl <n> polyvinyl <n> polyvinyl. <n> the polyvinyl <n> polyvinyl <n> the polyvinyl <n> polyvinyl <n> polyvinyl <n> polyvinyl <n> polyvinyl <n> polyvinyl.<n> the polyvinyl <n> polyvinyl.<n> the polyvinyl <n> polyvinyl <n> polyvinyl <n>.<n> <n> polyvinyl..<n> <n> polyvinyl.<n> it also.<n>.<n> it also.<n> it also <n> polyvinyl..<n> it also.<n> similarly.<n> similarly.<n> similarly.<n> similarly.<n> similarly.<n> additionally.<n> similarly.<n> similarly.<n> similarly.<n> similarly.<n> similarly.<n> similarly.<n> additionally.<n> similarly.<n> similarly.<n> similarly.<n> similarly.<n> similarly.<n> similarly.<n> additionally.<n> similarly.<n> it also.<n>.<n> similarly.<n> similarly.<n> similarly.<n> similarly.<n> similarly.<n> additionally.<n><n><n>.<n> similarly.<n> additionally.<n> similarly.<n> additionally.<n> similarly.<n> similarly.<n> additionally.<n> similarly.<n> similarly.<n> similarly.<n> similarly.<n> additionally.<n> similarly.<n> additionally.<n> additionally.<n> similarly.<n> similarly.<n> similarly.<n> additionally.<n> additionally.<n> additionally.<n> additionally.<n> additionally.<n> additionally.<n> additionally.<n> also.<n> similarly.<n> additionally.<n> additionally.<n>.<n> additionally.<n> additionally.<n> additionally.<n>.<n>']\n",
      "\n",
      "###############################################################################################################################################################\n",
      "\n",
      "< PROMPT >\n",
      "\n",
      "evidence 0: There is currently no consensus on whether CADASIL mutations generate hyperactive or hypoactive Notch3 proteins with regard to downstream signaling or whether CADASIL mutations are neutral in terms of Notch signaling. Whereas the R169C mutation appeared to lead to hyperactive Notch signaling (see above), the R1031C or C455R mutations were instead shown to be hypoactive,36[1] \n",
      "evidence 1: We believe that increased TGFb3 reflects an inflammatory condition and even an involvement of TGFb in fibrosis in CADASIL. Support for our hypothesis is the outcome of several studies that showed NOTCH3 and TGFb1 signalling play a key role in the pathogenesis and progression of chronic cardiovascular disease.[2] \n",
      "evidence 2: Over time, VSMCs apoptosis leads to fibrosis and thickening of the arterial wall, progressive lumen stenosis and vascular insufficiency that makes the already poorly perfused terminal regions particularly susceptible to infarcts. SMCs degeneration is followed by the emergence of large,...[3] \n",
      "evidence 3: Previously published studies have shown that TGF-b signaling is closely associated with the activity of SYK, and the kinase activity of SYK is essential for the activation of some signaling receptor downstream effector molecules[25]. ...bidirectional[33]. In the present study, the activation of SYK was shown to increase the progression of peritoneal fibrosis through activation of the TGF-b1/Smad3 signaling pathway, and inhibition of TGF-b1 also resulted in down-regulation of SYK.[4] \n",
      "evidence 4: Our work confirms and highlights the relevance of NOTCH3 expression and signaling in pro-inflammatory macrophage activation and identified its prominent and specific role in the activation of NF-kB. A positive regulation between NOTCH and NF-kB signaling pathway has been described previously in macrophages isolated from patients with atherosclerosis. In those patients, and in contrast with our results,[5] \n",
      "query: What is the therapeutic target for CADASIL? \n",
      "summarize given evidences and query:Syk is a therapeutic target for CADASIL. In CADASIL, proinflammatory signaling is activated[1] through the increase of TGFb1 signaling[2]. The apoptosis of vascular smooth muscle cell (VSMC) and increased TGFb1 signaling cause fibrosis and vascular abnormalities in vascular epithelial cells[3]. Syk increases fibrosis through activation of TGFb1 signaling[4]. \n",
      "\n",
      "evidence 0: Using both wild type mice and transgenic mice carrying the human mutant Notch3 gene (CADASIL mice), we have recently characterized the pathological features of CADASIL and determined the therapeutic efficacy of two hematopoietic growth factors, stem cell factor (SCF) and granulocyte colony-stimulating factor (G-CSF) in CADASIL. Our findings have revealed novel pathological changes in the endothelium of cerebral capillaries and in the neural stem cells (NSCs). We have also observed the impairment of cognitive function in CADASIL mice.[1] \n",
      "evidence 1: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common condition of hereditary stroke and vascular dementia. CADASIL is caused by Notch3 mutation, leading to progressive degeneration of vascular smooth muscle cells (VSMCs) of the small arteries in the brain. However, the pathogenesis of CADASIL remains largely unknown, and treatment that can stop or delay the progression of CADASIL is not yet available.[2] \n",
      "evidence 2: Today, CADASIL is known to every neurologist, but the disease has not yet revealed all its secrets. A lot of effort is still needed to understand the intimate mechanisms of the disease and the most efficient targets or approaches for the development of efficient therapeutics. The history of CADASIL will be further enriched by multiple ongoing research projects worldwide, at clinical and preclinical level, and will continue to enlighten research in the field of cerebral small vessel disorders.[3] \n",
      "query: what are the potential therapeutic targets for cadasil? \n",
      "summarize given evidences and query:\n",
      "\n",
      "\n",
      "< GENERATED >\n",
      "\n",
      "['evidence 0: is currently consensus on whether mutations generate hyperactive or hypoactive3 proteins with downstream signaling or whether mutations are neutral in terms of signaling proteins. <n> evidence 0: is currently consensus on whether mutations generate hyperactive or hypoactive3 proteins with downstream signaling or whether mutations are neutral in terms of signaling proteins. <n> evidence 0: is currently consensus on whether mutations generate hyperactive or hypoactive3 proteins with downstream signaling or whether mutations are neutral in terms of signaling proteins. <n> evidence 0: is currently consensus on whether mutations generate hyperactive or hypoactive3 proteins with downstream signaling or whether mutations are neutral in terms of signaling proteins. <n> evidence 0: is currently consensus on whether mutations generate hyperactive or hypoactive3 proteins with downstream signaling or whether mutations are neutral in terms of signaling proteins. <n> evidence 0: is currently consensus on whether mutations generate hyperactive or hypoactive3 proteins with downstream signaling or whether mutations are neutral in terms of signaling proteins.']\n",
      "\n",
      "###############################################################################################################################################################\n",
      "\n",
      "< PROMPT >\n",
      "\n",
      "evidence 0: There is currently no consensus on whether CADASIL mutations generate hyperactive or hypoactive Notch3 proteins with regard to downstream signaling or whether CADASIL mutations are neutral in terms of Notch signaling. Whereas the R169C mutation appeared to lead to hyperactive Notch signaling (see above), the R1031C or C455R mutations were instead shown to be hypoactive,36[1] \n",
      "evidence 1: Our work confirms and highlights the relevance of NOTCH3 expression and signaling in pro-inflammatory macrophage activation and identified its prominent and specific role in the activation of NF-kB. A positive regulation between NOTCH and NF-kB signaling pathway has been described previously in macrophages isolated from patients with atherosclerosis. In those patients, and in contrast with our results,[5] \n",
      "evidence 2: Niclosamide and derivatives - potent inhibitors of TMEM16A/F and Ca2+ signaling. NFA is a nonsteroidal anti-inflammatory compound that inhibits goblet cell degranulation and suppresses asthma phenotype (4, 27). ...This result suggests an antiinflammatory effect of niclosamide, which corresponds well to inhibition of allergic lung inflammation by the TMEM16A inhibitor benzbromarone (3, 31).[6] \n",
      "evidence 3: The key findings of this study are that (a) Cl- fluxes mediated by the Ca2+gated channel TMEM16A are a crucial determinant of pericyte tone; (b) TMEM16A is activated during ischemia and evokes a long-lasting pericytemediated capillary constriction that reduces CBF and favors neutrophil and platelet stalling; (c) genetic analysis suggests that increased TMEM16A expression is associated with poor recovery after ischemic stroke (and the genetic proxy[7] \n",
      "query: What is the therapeutic target for CADASIL? \n",
      "summarize given evidences and query:TMEM16A is a therapeutic target for CADASIL. Ischemia in CADASIL activates TMEM16A, Ca2+ gated Cl- channel, which regulates pericyte tone and induces capillary constriction[1]. Potent inhibitors of TMEM16A, niclosamide has antiinflammtory effect[2]. Niclosamide can suppress enhance inflammation in CADASIL[3]. \n",
      "\n",
      "evidence 0: Using both wild type mice and transgenic mice carrying the human mutant Notch3 gene (CADASIL mice), we have recently characterized the pathological features of CADASIL and determined the therapeutic efficacy of two hematopoietic growth factors, stem cell factor (SCF) and granulocyte colony-stimulating factor (G-CSF) in CADASIL. Our findings have revealed novel pathological changes in the endothelium of cerebral capillaries and in the neural stem cells (NSCs). We have also observed the impairment of cognitive function in CADASIL mice.[1] \n",
      "evidence 1: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common condition of hereditary stroke and vascular dementia. CADASIL is caused by Notch3 mutation, leading to progressive degeneration of vascular smooth muscle cells (VSMCs) of the small arteries in the brain. However, the pathogenesis of CADASIL remains largely unknown, and treatment that can stop or delay the progression of CADASIL is not yet available.[2] \n",
      "evidence 2: Today, CADASIL is known to every neurologist, but the disease has not yet revealed all its secrets. A lot of effort is still needed to understand the intimate mechanisms of the disease and the most efficient targets or approaches for the development of efficient therapeutics. The history of CADASIL will be further enriched by multiple ongoing research projects worldwide, at clinical and preclinical level, and will continue to enlighten research in the field of cerebral small vessel disorders.[3] \n",
      "query: what are the potential therapeutic targets for cadasil? \n",
      "summarize given evidences and query:\n",
      "\n",
      "\n",
      "< GENERATED >\n",
      "\n",
      "['in recent years there has been considerable progress in our understanding of the molecular and cellular mechanisms involved in the development of atherosclerosis. <n> however, this progress has been hampered by a lack of specificity in the terms used to define the disease, its progression, and treatment. in order to overcome this limitation, <n> we have focused our attention on the macrophage, a key cell type in atherosclerosis. in this review, <n> we summarize the recent advances in our understanding of the role of macrophage in atherosclerosis.']\n",
      "\n",
      "###############################################################################################################################################################\n",
      "\n",
      "< PROMPT >\n",
      "\n",
      "evidence 0: Here we report the characterization of the human Notch3 gene which we mapped to the CADASIL critical region. We have identified mutations in CADASIL patients that cause serious disruption of this gene, indicating that Notch3 could be the defective protein in CADASIL patients.All these missense mutations may result in severe disruption of the Notch3 protein, as suggested by the highly conserved nature of the aminoacid residues involved, particularly the cysteines that are key features of EGF likedomains24. These results indicate that these nucleotide substitutions are pathogenic mutations rather than rare polymorphisms.[1] \n",
      "evidence 1: Linkage studies in other families enabled further refinement of this genetic interval16,17 and identification of the mutated gene as NOTCH3 (Notch homolog 3).18[2] \n",
      "evidence 2: CADASIL, a hereditary vascular dementia, suggesting a role for Notch3 in vessel homeostasis (Joutel et al. 1996). CADASIL is a late-onset disorder, and neurological symptoms arise from a slowly developing systemic vasculopathy, characterized ultimately by degeneration of VSMC. ...maturation of VSMC, and ends around P28 when the artery acquires its final shape. We identify Notch3 to be the first key player of this process, by regulating cell-autonomously the arterial differentiation and maturation of VSMC.[3] \n",
      "query: What is the cause of the CADASIL? \n",
      "summarize given evidences and query:CADASIL is a rare hereditary cerebrovascular disease caused by a NOTCH3 mutation[1][2]. NOTCH3 is particularly important for the maturation of vascular smooth muscle cells (VSMCs). A decreased VSMC is a pathological hallmark for CADASIL[3]. \n",
      "\n",
      "evidence 0: Syk inhibition was found to stabilize microtubules and potentiate paclitaxel activity in cellular models of taxane-resistant ovarian cancers. We further studied the effects of Syk inhibition on paclitaxel activity in Syk(+) ovarian cancer cell models and in variants selected for taxane resistance. Syk inhibition was accomplished using RNAi and by exposure to the small molecule competitive inhibitor R406, the active metabolite of fostamatinib.[1] \n",
      "evidence 1: Therefore, inhibition of the inflammatory macrophages would be a promising approach to attenuate NASH. In this study, we studied the implication of SYK pathway in NASH, and investigated PLGA nanoparticles-based delivery of SYK pathway inhibitor as an effective and promising therapeutic approach for the treatment of NASH. We found positive correlation between SYK expression with the pathogenesis of NASH and alcoholic hepatitis in patients.[2] \n",
      "evidence 2: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common condition of hereditary stroke and vascular dementia. CADASIL is caused by Notch3 mutation, leading to progressive degeneration of vascular smooth muscle cells (VSMCs) of the small arteries in the brain. However, the pathogenesis of CADASIL remains largely unknown, and treatment that can stop or delay the progression of CADASIL is not yet available.[3] \n",
      "query: would SYK inhibition be potential treatment for cadasil? \n",
      "summarize given evidences and query:\n",
      "\n",
      "\n",
      "< GENERATED >\n",
      "\n",
      "['evidence 0: evidence 0: unknown characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene : we report characterization of human3 gene. evidence 0: evidence 0: evidence 0: evidence 0 : evidence 0 : evidence 0 : evidence 0: evidence 0 : evidence 0: evidence 0 : evidence 0. evidence 0 : evidence 0 : evidence 0. evidence 0 : evidence 0. evidence 0 : evidence 0. evidence 0. evidence 0 : evidence 0. evidence 0. evidence 0. evidence 0. evidence 0. evidence 0. evidence 0. evidence 0. evidence 0. evidence 0. evidence 0. evidence 0. evidence 0. evidence 0. evidence 0. evidence 0. evidence 0. <n> evidence 0. <n> evidence 0. the results. <n> evidence 0.. the results.. the results... the results...... the results... the results...... <n> the extent the extent the extent the extent the extent the nature. the extent the extent the nature. the extent the extent the nature. the nature. the nature. the nature. the nature. the nature. the nature. the effects of the nature. the nature. the effects of the nature. the effects of the nature. the nature. the nature. the nature. the nature. the effects of the nature. the effects also the interactions. the effects of the nature. the interactions. the effects of the interactions. the effects of the contr contr contr saccharin saccharin saccharin saccharin saccharin saccharin. the saccharin saccharin also the saccharin also the also the also the also the predominates. the predominates. the interactions. the interactions. the clinical and the interactions. the interactions. the interactions. the interactions also the clinical and the interactions. the gene. the interactions also the clinical <n> the clinical. <n> the temper the temper the clinical. <n> the also the clinical the clinical <n> the clinical <n> the melatonin melatonin melatonin melatonin melatonin melatonin melatonin melatonin melatonin melatonin melatonin melatonin melatonin melatonin melatonin melatonin melatonin melatonin also the clinical <n> the clinical. <n> the clinical <n> the clinical. <n> the clinical <n> the melatonin melatonin melatonin melatonin melatonin melatonin melatonin melatonin melatonin also the interactions also the interactions <n> the clinical <n> the clinical <n> the clinical <n> the interactions. <n> thedisqualification <n> the interactions also the interactions also the suppression.']\n",
      "\n",
      "###############################################################################################################################################################\n",
      "\n",
      "< PROMPT >\n",
      "\n",
      "evidence 0: There is currently no consensus on whether CADASIL mutations generate hyperactive or hypoactive Notch3 proteins with regard to downstream signaling or whether CADASIL mutations are neutral in terms of Notch signaling. Whereas the R169C mutation appeared to lead to hyperactive Notch signaling (see above), the R1031C or C455R mutations were instead shown to be hypoactive,36[1] \n",
      "evidence 1: We believe that increased TGFb3 reflects an inflammatory condition and even an involvement of TGFb in fibrosis in CADASIL. Support for our hypothesis is the outcome of several studies that showed NOTCH3 and TGFb1 signalling play a key role in the pathogenesis and progression of chronic cardiovascular disease.[2] \n",
      "evidence 2: Over time, VSMCs apoptosis leads to fibrosis and thickening of the arterial wall, progressive lumen stenosis and vascular insufficiency that makes the already poorly perfused terminal regions particularly susceptible to infarcts. SMCs degeneration is followed by the emergence of large,...[3] \n",
      "evidence 3: Previously published studies have shown that TGF-b signaling is closely associated with the activity of SYK, and the kinase activity of SYK is essential for the activation of some signaling receptor downstream effector molecules[25]. ...bidirectional[33]. In the present study, the activation of SYK was shown to increase the progression of peritoneal fibrosis through activation of the TGF-b1/Smad3 signaling pathway, and inhibition of TGF-b1 also resulted in down-regulation of SYK.[4] \n",
      "evidence 4: Our work confirms and highlights the relevance of NOTCH3 expression and signaling in pro-inflammatory macrophage activation and identified its prominent and specific role in the activation of NF-kB. A positive regulation between NOTCH and NF-kB signaling pathway has been described previously in macrophages isolated from patients with atherosclerosis. In those patients, and in contrast with our results,[5] \n",
      "query: What is the therapeutic target for CADASIL? \n",
      "summarize given evidences and query:Syk is a therapeutic target for CADASIL. In CADASIL, proinflammatory signaling is activated[1] through the increase of TGFb1 signaling[2]. The apoptosis of vascular smooth muscle cell (VSMC) and increased TGFb1 signaling cause fibrosis and vascular abnormalities in vascular epithelial cells[3]. Syk increases fibrosis through activation of TGFb1 signaling[4]. \n",
      "\n",
      "evidence 0: Syk inhibition was found to stabilize microtubules and potentiate paclitaxel activity in cellular models of taxane-resistant ovarian cancers. We further studied the effects of Syk inhibition on paclitaxel activity in Syk(+) ovarian cancer cell models and in variants selected for taxane resistance. Syk inhibition was accomplished using RNAi and by exposure to the small molecule competitive inhibitor R406, the active metabolite of fostamatinib.[1] \n",
      "evidence 1: Therefore, inhibition of the inflammatory macrophages would be a promising approach to attenuate NASH. In this study, we studied the implication of SYK pathway in NASH, and investigated PLGA nanoparticles-based delivery of SYK pathway inhibitor as an effective and promising therapeutic approach for the treatment of NASH. We found positive correlation between SYK expression with the pathogenesis of NASH and alcoholic hepatitis in patients.[2] \n",
      "evidence 2: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common condition of hereditary stroke and vascular dementia. CADASIL is caused by Notch3 mutation, leading to progressive degeneration of vascular smooth muscle cells (VSMCs) of the small arteries in the brain. However, the pathogenesis of CADASIL remains largely unknown, and treatment that can stop or delay the progression of CADASIL is not yet available.[3] \n",
      "query: would SYK inhibition be potential treatment for cadasil? \n",
      "summarize given evidences and query:\n",
      "\n",
      "\n",
      "< GENERATED >\n",
      "\n",
      "['evidence 0: currently, there is no consensus on whether mutations generate hypoactive or hyperactive signaling or whether they are effective in terms of signaling. <n> evidence 0: currently, there is no consensus on whether activation or inhibition of signaling is therapeutic. <n> evidence 0: currently, there is no consensus on whether activation or inhibition of signaling is therapeutic. <n> evidence 0: currently, there is no consensus on whether activation or inhibition of signaling is therapeutic. <n> evidence 0: currently, there is no consensus on whether activation or inhibition of signaling is therapeutic. <n> evidence 0: currently, there is no consensus on whether activation or inhibition of signaling is therapeutic. <n> evidence 0: currently, there is no consensus on whether activation or inhibition of signaling is therapeutic. <n> evidence 0: currently, there is no consensus on whether activation or inhibition of signaling is therapeutic. <n> evidence 0: currently, there is no consensus on whether activation or inhibition of signaling is therapeutic. <n> evidence 0: currently, there is no consensus on whether activation or inhibition of signaling is therapeutic.']\n",
      "\n",
      "###############################################################################################################################################################\n",
      "\n",
      "< PROMPT >\n",
      "\n",
      "evidence 0: There is currently no consensus on whether CADASIL mutations generate hyperactive or hypoactive Notch3 proteins with regard to downstream signaling or whether CADASIL mutations are neutral in terms of Notch signaling. Whereas the R169C mutation appeared to lead to hyperactive Notch signaling (see above), the R1031C or C455R mutations were instead shown to be hypoactive,36[1] \n",
      "evidence 1: Our work confirms and highlights the relevance of NOTCH3 expression and signaling in pro-inflammatory macrophage activation and identified its prominent and specific role in the activation of NF-kB. A positive regulation between NOTCH and NF-kB signaling pathway has been described previously in macrophages isolated from patients with atherosclerosis. In those patients, and in contrast with our results,[5] \n",
      "evidence 2: Niclosamide and derivatives - potent inhibitors of TMEM16A/F and Ca2+ signaling. NFA is a nonsteroidal anti-inflammatory compound that inhibits goblet cell degranulation and suppresses asthma phenotype (4, 27). ...This result suggests an antiinflammatory effect of niclosamide, which corresponds well to inhibition of allergic lung inflammation by the TMEM16A inhibitor benzbromarone (3, 31).[6] \n",
      "evidence 3: The key findings of this study are that (a) Cl- fluxes mediated by the Ca2+gated channel TMEM16A are a crucial determinant of pericyte tone; (b) TMEM16A is activated during ischemia and evokes a long-lasting pericytemediated capillary constriction that reduces CBF and favors neutrophil and platelet stalling; (c) genetic analysis suggests that increased TMEM16A expression is associated with poor recovery after ischemic stroke (and the genetic proxy[7] \n",
      "query: What is the therapeutic target for CADASIL? \n",
      "summarize given evidences and query:TMEM16A is a therapeutic target for CADASIL. Ischemia in CADASIL activates TMEM16A, Ca2+ gated Cl- channel, which regulates pericyte tone and induces capillary constriction[1]. Potent inhibitors of TMEM16A, niclosamide has antiinflammtory effect[2]. Niclosamide can suppress enhance inflammation in CADASIL[3]. \n",
      "\n",
      "evidence 0: Syk inhibition was found to stabilize microtubules and potentiate paclitaxel activity in cellular models of taxane-resistant ovarian cancers. We further studied the effects of Syk inhibition on paclitaxel activity in Syk(+) ovarian cancer cell models and in variants selected for taxane resistance. Syk inhibition was accomplished using RNAi and by exposure to the small molecule competitive inhibitor R406, the active metabolite of fostamatinib.[1] \n",
      "evidence 1: Therefore, inhibition of the inflammatory macrophages would be a promising approach to attenuate NASH. In this study, we studied the implication of SYK pathway in NASH, and investigated PLGA nanoparticles-based delivery of SYK pathway inhibitor as an effective and promising therapeutic approach for the treatment of NASH. We found positive correlation between SYK expression with the pathogenesis of NASH and alcoholic hepatitis in patients.[2] \n",
      "evidence 2: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common condition of hereditary stroke and vascular dementia. CADASIL is caused by Notch3 mutation, leading to progressive degeneration of vascular smooth muscle cells (VSMCs) of the small arteries in the brain. However, the pathogenesis of CADASIL remains largely unknown, and treatment that can stop or delay the progression of CADASIL is not yet available.[3] \n",
      "query: would SYK inhibition be potential treatment for cadasil? \n",
      "summarize given evidences and query:\n",
      "\n",
      "\n",
      "< GENERATED >\n",
      "\n",
      "['key clinical messagewe summarize the results of a study on the role of interleukin-6 ( il-6 ) in the development of lung cancer. <n> we summarize the findings of a study on the role of il-6 in the pathogenesis of chronic obstructive pulmonary disease ( copd ). <n> we summarize the findings of a study on the role of tumor necrosis factor alpha ( tnf- ) in the development of lung cancer. <n> we summarize the findings of a study on the role of tumor necrosis factor alpha ( tnf- ) in the pathogenesis of chronic obstructive pulmonary disease. <n> we summarize the findings of a study on the role of tumor necrosis factor alpha ( tnf- ) in the pathogenesis of chronic obstructive pulmonary disease. <n> we summarize the findings of a study on the role of tumor necrosis factor alpha ( tnf- ) in the pathogenesis of chronic obstructive pulmonary disease. <n> we summarize the findings of a study on the role of tumor necrosis factor alpha ( tnf- ) in the pathogenesis of chronic obstructive pulmonary disease.']\n",
      "\n",
      "###############################################################################################################################################################\n",
      "\n"
     ]
    }
   ],
   "source": [
    "\n",
    "with open(f\"generation_results_{model_name.replace('/', '-')}_one-shot.txt\", \"w\") as results: # mujeen_\n",
    "    results.write(f'<< Model: {model_name} >>\\n\\n')\n",
    "    # results.write()\n",
    "\n",
    "    for i in range(len(args)):\n",
    "    # for i in range(1):\n",
    "        example, query = args[i] # 무진님꺼할땐 indexing 빼기\n",
    "        prompt = make_prompt(example, query)\n",
    "        \n",
    "        print('< PROMPT >\\n')\n",
    "        print(prompt)\n",
    "        results.write('< PROMPT >\\n\\n')\n",
    "        results.write(prompt)\n",
    "        \n",
    "        # inputs = tokenizer(prompt, return_tensors=\"pt\", max_length=2048, truncation=True)\n",
    "        inputs = tokenizer(prompt, return_tensors=\"pt\", max_length=1024, truncation=True)\n",
    "        inputs.to(device)\n",
    "        outputs = model.generate(**inputs, max_length=1024)\n",
    "        generated = tokenizer.batch_decode(outputs, skip_special_tokens=True)\n",
    "        \n",
    "        print('\\n\\n< GENERATED >\\n')\n",
    "        print(generated)\n",
    "        print('\\n###############################################################################################################################################################\\n')\n",
    "        results.write('\\n\\n< GENERATED >\\n\\n')\n",
    "        results.write(*generated)\n",
    "        results.write('\\n\\n###############################################################################################################################################################\\n')\n",
    "        \n",
    "results.close()\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "< PROMPT >\n",
      "\n",
      "evidence 0: Here we report the characterization of the human Notch3 gene which we mapped to the CADASIL critical region. We have identified mutations in CADASIL patients that cause serious disruption of this gene, indicating that Notch3 could be the defective protein in CADASIL patients. All these missense mutations may result in severe disruption of the Notch3 protein, as suggested by the highly conserved nature of the aminoacid residues involved, particularly the cysteines that are key features of EGF likedomains24. These results indicate that these nucleotide substitutions are pathogenic mutations rather than rare polymorphisms. \n",
      "evidence 1: Linkage studies in other families enabled further refinement of this genetic interval16,17 and identification of the mutated gene as NOTCH3 (Notch homolog 3).18 \n",
      "evidence 2: There is currently no consensus on whether CADASIL mutations generate hyperactive or hypoactive Notch3 proteins with regard to downstream signaling or whether CADASIL mutations are neutral in terms of Notch signaling. Whereas the R169C mutation appeared to lead to hyperactive Notch signaling (see above), the R1031C or C455R mutations were instead shown to be hypoactive,36  \n",
      "query: What is the cause of the CADASIL? \n",
      "summarize given evidences and query:\n",
      "\n",
      "\n",
      "< GENERATED >\n",
      "\n",
      "[\"mutations in the coding region of the human transcription factor 3 ( tf3 ) gene have been identified in a large number of patients with alzheimer's disease ( ad ), parkinson's disease ( pd ), and alzheimer's disease ( ad ). <n> these mutations have led to loss of function of tf3 in human cells, resulting in loss of the ability of these cells to mount alzheimer's disease - specific t - cell response. <n> these results indicate that tf3 is a critical factor in the pathogenesis of alzheimer's disease.\"]\n",
      "\n",
      "###############################################################################################################################################################\n",
      "\n"
     ]
    }
   ],
   "source": [
    "with open(f\"generation_results_mujeen_{model_name.replace('/', '-')}_zero-shot.txt\", \"w\") as results:\n",
    "    results.write(f'<< Model: {model_name} >>\\n\\n')\n",
    "    # results.write()\n",
    "\n",
    "    # for i in range(len(args)):\n",
    "    for i in range(1):\n",
    "        example, query = args #[i]\n",
    "        prompt = make_prompt(example, query, zeroshot=True)\n",
    "        \n",
    "        print('< PROMPT >\\n')\n",
    "        print(prompt)\n",
    "        results.write('< PROMPT >\\n\\n')\n",
    "        results.write(prompt)\n",
    "        \n",
    "        inputs = tokenizer(prompt, return_tensors=\"pt\", max_length=1024, truncation=True)\n",
    "        inputs.to(device)\n",
    "        outputs = model.generate(**inputs, max_length=1024)\n",
    "        generated = tokenizer.batch_decode(outputs, skip_special_tokens=True)\n",
    "        \n",
    "        print('\\n\\n< GENERATED >\\n')\n",
    "        print(generated)\n",
    "        print('\\n###############################################################################################################################################################\\n')\n",
    "        results.write('\\n\\n< GENERATED >\\n\\n')\n",
    "        results.write(*generated)\n",
    "        results.write('\\n\\n###############################################################################################################################################################\\n')\n",
    "        \n",
    "results.close()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "# inputs = tokenizer(prompt, return_tensors=\"pt\", max_length=2048, truncation=True)\n",
    "# outputs = model.generate(**inputs, max_length=2048)\n",
    "# print(tokenizer.batch_decode(outputs, skip_special_tokens=True))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "mujeen_input_text = \"\"\"evidence 0: There is currently no consensus on whether CADASIL mutations generate hyperactive or hypoactive Notch3 proteins with regard to downstream signaling or whether CADASIL mutations are neutral in terms of Notch signaling. Whereas the R169C mutation appeared to lead to hyperactive Notch signaling (see above), the R1031C or C455R mutations were instead shown to be hypoactive,36 \n",
    "evidence 1: We believe that increased TGFb3 reflects an inflammatory condition and even an involvement of TGFb in fibrosis in CADASIL. Support for our hypothesis is the outcome of several studies that showed NOTCH3 and TGFb1 signalling play a key role in the pathogenesis and progression of chronic cardiovascular disease. \n",
    "evidence 2: Over time, VSMCs apoptosis leads to fibrosis and thickening of the arterial wall, progressive lumen stenosis and vascular insufficiency that makes the already poorly perfused terminal regions particularly susceptible to infarcts. SMCs degeneration is followed by the emergence of large \n",
    "evidence 3: Previously published studies have shown that TGF-b signaling is closely associated with the activity of SYK, and the kinase activity of SYK is essential for the activation of some signaling receptor downstream effector molecules. In the present study, the activation of SYK was shown to increase the progression of peritoneal fibrosis through activation of the TGF-b1/Smad3 signaling pathway, and inhibition of TGF-b1 also resulted in down-regulation of SYK. \n",
    "evidence 4: Our work confirms and highlights the relevance of NOTCH3 expression and signaling in pro-inflammatory macrophage activation and identified its prominent and specific role in the activation of NF-κB. A positive regulation between NOTCH and NF-κB signaling pathway has been described previously in macrophages isolated from patients with atherosclerosis. In those patients, and in contrast with our results, \n",
    "query: What is the therapeutic target for CADASIL? \n",
    "summarize given evidences and query: Syk is a therapeutic target for CADASIL. In CADASIL, proinflammatory signaling is activated through the increase of TGFb1 signaling. The apoptosis of vascular smooth muscle cell (VSMC) and increased TGFb1 signaling cause fibrosis and vascular abnormalities in vascular epithelial cells. Syk increases fibrosis through activation of TGF-b1 signaling. \n",
    "\n",
    "evidence 0: Here we report the characterization of the human Notch3 gene which we mapped to the CADASIL critical region. We have identified mutations in CADASIL patients that cause serious disruption of this gene, indicating that Notch3 could be the defective protein in CADASIL patients. All these missense mutations may result in severe disruption of the Notch3 protein, as suggested by the highly conserved nature of the aminoacid residues involved, particularly the cysteines that are key features of EGF likedomains24. These results indicate that these nucleotide substitutions are pathogenic mutations rather than rare polymorphisms. \n",
    "evidence 1: Linkage studies in other families enabled further refinement of this genetic interval16,17 and identification of the mutated gene as NOTCH3 (Notch homolog 3).18 \n",
    "evidence 2: CADASIL, a hereditary vascular dementia, suggesting a role for Notch3 in vessel homeostasis (Joutel et al. 1996). CADASIL is a late-onset disorder, and neurological symptoms arise from a slowly developing systemic vasculopathy, characterized ultimately by degeneration of vSMC . maturation of vSMC, and ends around P28 when the artery acquires its final shape. We identify Notch3 to be the first key player of this process, by regulating cell-autonomously the arterial differentiation and maturation of vSMC. \n",
    "query: What is the cause of the CADASIL? \n",
    "summarize given evidences and query:\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [],
   "source": [
    "evidence_input = \"\"\"Evidence: Here we report the characterization of the human Notch3 gene which we mapped to the CADASIL critical region. We have identified mutations in CADASIL patients that cause serious disruption of this gene, indicating that Notch3 could be the defective protein in CADASIL patients.All these missense mutations may result in severe disruption of the Notch3 protein, as suggested by the highly conserved nature of the aminoacid residues involved, particularly the cysteines that are key features of EGF likedomains24. These results indicate that these nucleotide substitutions are pathogenic mutations rather than rare polymorphisms.\n",
    "Summarize the evidence: In the evidence, it is mentioned that mutations were identified in CADASIL patients and that it may result in severe disruption of the Notch3 protein.\n",
    "\n",
    "Evidence: CADASIL, a hereditary vascular dementia, suggesting a role for Notch3 in vessel homeostasis (Joutel et al. 1996). CADASIL is a late-onset disorder, and neurological symptoms arise from a slowly developing systemic vasculopathy, characterized ultimately by degeneration of vSMC . maturation of vSMC, and ends around P28 when the artery acquires its final shape. We identify Notch3 to be the first key player of this process, by regulating cell-autonomously the arterial differentiation and maturation of vSMC. \n",
    "Summarize the evidence:\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "input_text = \"\"\"evidence 0: There is currently no consensus on whether CADASIL mutations generate hyperactive or hypoactive Notch3 proteins with regard to downstream signaling or whether CADASIL mutations are neutral in terms of Notch signaling. Whereas the R169C mutation appeared to lead to hyperactive Notch signaling (see above), the R1031C or C455R mutations were instead shown to be hypoactive,36 \n",
    "evidence 1: We believe that increased TGFb3 reflects an inflammatory condition and even an involvement of TGFb in fibrosis in CADASIL. Support for our hypothesis is the outcome of several studies that showed NOTCH3 and TGFb1 signalling play a key role in the pathogenesis and progression of chronic cardiovascular disease. \n",
    "evidence 2: Over time, VSMCs apoptosis leads to fibrosis and thickening of the arterial wall, progressive lumen stenosis and vascular insufficiency that makes the already poorly perfused terminal regions particularly susceptible to infarcts. SMCs degeneration is followed by the emergence of large \n",
    "evidence 3: Previously published studies have shown that TGF-b signaling is closely associated with the activity of SYK, and the kinase activity of SYK is essential for the activation of some signaling receptor downstream effector molecules. In the present study, the activation of SYK was shown to increase the progression of peritoneal fibrosis through activation of the TGF-b1/Smad3 signaling pathway, and inhibition of TGF-b1 also resulted in down-regulation of SYK. \n",
    "evidence 4: Our work confirms and highlights the relevance of NOTCH3 expression and signaling in pro-inflammatory macrophage activation and identified its prominent and specific role in the activation of NF-κB. A positive regulation between NOTCH and NF-κB signaling pathway has been described previously in macrophages isolated from patients with atherosclerosis. In those patients, and in contrast with our results, \n",
    "query: What is the therapeutic target for CADASIL? \n",
    "summarize given evidences and query: Syk is a therapeutic target for CADASIL. In CADASIL, proinflammatory signaling is activated through the increase of TGFb1 signaling. The apoptosis of vascular smooth muscle cell (VSMC) and increased TGFb1 signaling cause fibrosis and vascular abnormalities in vascular epithelial cells. Syk increases fibrosis through activation of TGF-b1 signaling. \n",
    "\n",
    "evidence 0: CADASIL) is sometimes misdiagnosed as multiple sclerosis (MS). MS and CADASIL are not known to co-occur and brain magnetic resonance imagining (MRI) findings can help with differential diagnosis. Despite the availability of this information, a case report is presented of a 61-year-old woman who was misdiagnosed with MS at age 50, tested positive for CADASIL at age 56, described incorrectly as having both conditions simultaneously, and continued on MS disease-modifying medications, resulting in financial and physical hardship.\n",
    "evidence 1: Despite the availability of this information, a case report is presented of a 61-year-old woman who was misdiagnosed with MS at age 50, tested positive for CADASIL at age 56, described incorrectly as having both conditions simultaneously, and continued on MS disease-modifying medications, resulting in financial and physical hardship. Neuropsychological consultation helped initiate removal of the MS diagnosis and treatment. Better understanding is needed among clinicians that MS and CADASIL are not known to co-exist, that no association has been found between MS and the NOTCH3 mutations that cause CADASIL, and that neuroimaging and clinical features can help distinguish between the two conditions in addition to genetic testing.\n",
    "evidence 2: Antithrombotic drugs were used in three patients, in one for an unrelated coexisting prothrombotic condition. CADASIL does not seem to be associated with an unfavorable outcome of pregnancy either for women and fetuses. Patients and treating physicians should be reassured that pregnancy can be safely initiated in CADASIL, as there is no evidence to support a specific preventive antithrombotic treatment during pregnancy in CADASIL.\n",
    "query: can nilvadipine help alleviate cadasil symptoms?\n",
    "summarize given evidences and query:\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [],
   "source": [
    "input_text = \"\"\"evidence 0: Here we report the characterization of the human Notch3 gene which we mapped to the CADASIL critical region. We have identified mutations in CADASIL patients that cause serious disruption of this gene, indicating that Notch3 could be the defective protein in CADASIL patients.All these missense mutations may result in severe disruption of the Notch3 protein, as suggested by the highly conserved nature of the aminoacid residues involved, particularly the cysteines that are key features of EGF likedomains24. These results indicate that these nucleotide substitutions are pathogenic mutations rather than rare polymorphisms. \n",
    "evidence 1: Linkage studies in other families enabled further refinement of this genetic interval16,17 and identification of the mutated gene as NOTCH3 (Notch homolog 3).18 \n",
    "evidence 2: CADASIL, a hereditary vascular dementia, suggesting a role for Notch3 in vessel homeostasis (Joutel et al. 1996). CADASIL is a late-onset disorder, and neurological symptoms arise from a slowly developing systemic vasculopathy, characterized ultimately by degeneration of VSMC . maturation of vSMC, and ends around P28 when the artery acquires its final shape. We identify Notch3 to be the first key player of this process, by regulating cell-autonomously the arterial differentiation and maturation of vSMC.\n",
    "query: What is the cause of the CADASIL?\n",
    "summarize given evidences given the query: In evidence 0, it is mentioned that mutations were identified in CADASIL patients and that it may result in severe disruption of the Notch3 protein. In evidence 1, it is mentioned that the mutated gene was identified as NOTCH3. In evidence 2, it is mentioned that Notch3 is the first key player in the maturation of VSMCs.\n",
    "\n",
    "evidence 0: “Role of NOTCH3 Mutations in the Cerebral Small Vessel Disease Cerebral Autosomal Dominant Arteriopathy ... (Stroke 2018)” There is currently no consensus on whether CADASIL mutations generate hyperactive or hypoactive Notch3 proteins with …\n",
    "evidence 1: “Differences in proliferation rate between CADASIL and control vascular smooth muscle cells are ... (J Cell Mol Med 2018)” We believe that increased TGFb3 reflects an inflammatory condition and even an involvement of TGFb in fibrosis in CADASIL. … showed NOTCH3 and TGFb1 signalling play a key role in the pathogenesis and progression of chronic …\n",
    "evidence 2: “The Role of Vascular Smooth Muscle Cells in Arterial Remodeling: Focus on Calcification ... (Int J Mol Sci 2019)” Over time, VSMCs apoptosis leads to fibrosis and thickening of the arterial wall, progressive lumen stenosis and vascular insufficiency that makes the already poorly perfused …\n",
    "query: What is the therapeutic target for CADASIL?\n",
    "summarize given evidences given the query: \"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "input_text = \"\"\"Evidence 0: Here we report the characterization of the human Notch3 gene which we mapped to the CADASIL critical region. We have identified mutations in CADASIL patients that cause serious disruption of this gene, indicating that Notch3 could be the defective protein in CADASIL patients.All these missense mutations may result in severe disruption of the Notch3 protein, as suggested by the highly conserved nature of the aminoacid residues involved, particularly the cysteines that are key features of EGF likedomains24. These results indicate that these nucleotide substitutions are pathogenic mutations rather than rare polymorphisms. \n",
    "Evidence 1: Linkage studies in other families enabled further refinement of this genetic interval16,17 and identification of the mutated gene as NOTCH3 (Notch homolog 3).18 \n",
    "Evidence 2: CADASIL, a hereditary vascular dementia, suggesting a role for Notch3 in vessel homeostasis (Joutel et al. 1996). CADASIL is a late-onset disorder, and neurological symptoms arise from a slowly developing systemic vasculopathy, characterized ultimately by degeneration of VSMC . maturation of vSMC, and ends around P28 when the artery acquires its final shape. We identify Notch3 to be the first key player of this process, by regulating cell-autonomously the arterial differentiation and maturation of vSMC.\n",
    "Query: What is the cause of the CADASIL?\n",
    "Summarization of evidences given the query:\n",
    "CADASIL is a rare hereditary cerebrovascular disease caused by a NOTCH3 mutation[1][2]. NOTCH3 is particularly important for the maturation of vascular smooth muscle cells (VSMCs). A decreased VSMC is a pathological hallmark for CADASIL[3].\n",
    "\n",
    "Evidence 0: “Role of NOTCH3 Mutations in the Cerebral Small Vessel Disease Cerebral Autosomal Dominant Arteriopathy … (Stroke 2018)” There is currently no consensus on whether CADASIL mutations generate hyperactive or hypoactive Notch3 proteins with …\n",
    "Evidence 1: “Differences in proliferation rate between CADASIL and control vascular smooth muscle cells are … (J Cell Mol Med 2018)” We believe that increased TGFb3 reflects an inflammatory condition and even an involvement of TGFb in fibrosis in CADASIL. … showed NOTCH3 and TGFb1 signalling play a key role in the pathogenesis and progression of chronic …\n",
    "Evidence 2: “The Role of Vascular Smooth Muscle Cells in Arterial Remodeling: Focus on Calcification … (Int J Mol Sci 2019)” Over time, VSMCs apoptosis leads to fibrosis and thickening of the arterial wall, progressive lumen stenosis and vascular insufficiency that makes the already poorly perfused …\n",
    "Evidence 3: “Spleen Tyrosine Kinase (SYK) in the Progression of Peritoneal Fibrosis Through Activation of the … (Med Sci Monit 2019)” Previously published studies have shown that TGF-b signaling is closely associated with the activity of SYK, and the kinase …\n",
    "Evidence 4: “NOTCH3 signaling is essential for NF-κB activation in TLRactivated macrophages (Sci Rep 2020)” Our work confirms and highlights the relevance of NOTCH3 expression and signaling in pro-inflammatory macrophage …\n",
    "Evidence 5: “Niclosamide repurposed for the treatment of inflammatory airway disease (JCI Insight 2019)” Niclosamide and derivatives — potent inhibitors of TMEM16A/F and Ca2+ signaling. NFA is a nonsteroidal antiinflammatory compound that inhibits goblet …\n",
    "Evidence 6: “The Ca2+-gated channel TMEM16A amplifies capillary pericyte contraction and reduces … (J Clin Invest. 2022)” The key findings of this study are that (a) Cl– fluxes mediated by the Ca2+-gated channel TMEM16A are a crucial determinant of pericyte tone\n",
    "Query: What is the therapeutic target for CADASIL?\n",
    "Summarization of evidences given the query: \"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "py39",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.16"
  },
  "vscode": {
   "interpreter": {
    "hash": "ce5cb1d3583c4bc4c26ba2d9d1424221025f98623b08f3ff314497f7b1d6b7f8"
   }
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
